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ABSTRACT 
Detonation nanodiamonds (NDs), due to their 4-5 nm primary particle size, stable inert 
core, reactive surface, ability to form hydrogel, are emerging as intracellular delivery vehicle for 
small and large molecules. Despite several favorable characteristics, the use of NDs in biological 
systems is impeded by their high aggregation propensity in polar liquid medium. To develop 
NDs as potential gene delivery vectors, pristine carboxylated NDs (pNDs) were functionalized 
with lysine through covalent conjugation. Raman and FTIR spectroscopic determinations 
confirmed the functionalization of NDs with lysine molecules, while thermogravimetric analysis 
estimated a surface loading of 1.7 mmol/g. Through lysine-functionalization, the dispersion 
stability of NDs in water increased considerably, showing a zeta potential of +49 mV. The 
average particle size of pNDs as measured by dynamic light scattering was substantially reduced 
from 1281 to 21 nm after lysine functionalization. Atomic force microscopy further substantiated 
the disaggregation of pNDs achieved through lysine functionalization. The lysine-functionalized 
NDs (fNDs) were able to electrostatically bind and block the migration of the nucleic acids at a 
weight ratio of 5:1 and 20:1 of fNDs:pDNA and fNDs:siRNA, respectively, with a shift in zeta 
potential from negative to positive value. The particle size of the complexes stabilized around 
110 nm for fNDs-pDNA and less than 280 nm for fNDs-siRNA at the weight ratios of 50:1 
fNDs:nucleic acid. While the Raman-fluorescence maps were equivocal with regards to the 
cellular association of NDs, backscattering maps clearly indicated the interaction of the fNDs 
with the cells. Cellular internalization of a few fNDs was suggested by laser confocal scanning 
microscopy. MTT assay demonstrated no significant in vitro cytotoxicity of pNDs and fNDs in 
the concentration range from 4 to 250 µg/mL. Flow cytometeric assessment of the gene 
expression (GFP intensity measurements) suggested that a strong binding of siRNA with fNDs 
might have prevented the release of nucleic acid into the cytoplasm of the cells. 
Overall, in this study, stable aqueous dispersion of NDs was generated using a 
mechanochemical approach feasible at a small laboratory scale, and early evidence was 
presented that the fNDs can be optimized for safe delivery of nucleic acids into mammalian cells. 
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INTRODUCTION 
 
Applications of detonation nanodiamonds (NDs) are gaining rapid significance in the 
biological sciences due to their favorable structural, chemical, optical and biological properties. 
NDs can improve the physiochemical characteristics and intracellular delivery of small 
molecules, large molecules and biotechnological products [1-4]. The intrinsic and induced 
fluorescence of NDs is a key feature for their use as cellular biomarkers [5,6]. However, NDs 
possess a strong tendency to aggregate to form micron-sized particles, when dispersed in a polar 
liquid media. These aggregated particles can induce toxic effects in the biological systems by 
blocking the vasculature and triggering immune responses [7]. Aggregation is also an 
impediment in cellular internalization [8]. 
 Although ND dispersions of less than 10 nm particles were attained by high energy 
bead-assisted probe sonication in literature, the potential of contamination of the samples with 
sonotrode material and beads [9,10], and the risk of altering the intrinsic diamond structure is 
high. These deficiencies warrant research exploring an alternative, non-contaminating 
disaggregation approach that is feasible in laboratory settings. Functionalization of the NDs 
accompanied by the simple mechanical treatment could lead to the disaggregation of ND 
aggregates as well as produce a surface enriched in functional groups that could subsequently 
facilitate a higher loading of cargo, ultimately improving drug delivery efficiency. 
Gene therapy is emerging as a promising alternative to conventional drug therapy for 
various inherited and acquired disorders [11]. However, there is a challenge to effectively deliver 
the transgene into the targeted cellular compartment due to its anionic nature and high molecular 
weight. For an effective cellular internalization and subsequent gene expression, the particles 
size of the carrier-genetic material should be less than 300 nm [12]. An overall positive charge 
on the complex is required for their effective cellular internalization [13,14] and endosomal 
release of the genetic material [14]. In addition, an optimal surface charge prevents aggregation 
of the nanoparticles and contributes to the overall colloidal stability of the dispersion.  
Among various investigated non-viral vectors of the genetic materials, positively charged 
detonation NDs could emerge as the promising delivery candidates due to their biocompatibility, 
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nano-size and favorable surface chemistry for conjugating biomolecules [15]. In addition, the 
solid core of NDs could provide an additional advantage over soft nanoparticles (polymers and 
lipids) of protecting the attached genetic material from extracellular environmental changes and 
nuclease attack.  
Therefore, my aim was to develop a methodology to generate a disaggregated population 
of NDs that could serve as vectors to deliver genetic materials across the cellular membranes. 
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                                                                                                                     Chapter 1
NANOTECHNOLOGY IN RELATION TO THE GENE THERAPY 
 Overview of Nanotechnology 1.1
Nanotechnology is a rapidly expanding field, dealing with the development of nano-sized 
materials, along with the techniques and equipment functioning at the nano-scale. According to 
Health Canada, at least one dimension of nanomaterials should be from 1 through 100 nm, or the 
nanomaterial should show novel nano-scale characteristic(s) when all the dimensions fall out of 
this range [16]. Since aggregation and functionalization can have a substantial effect on the size 
of some of the particles to exclude them from the nano category, the dimensions of the internal 
structure of particle were suggested to be included in the definition [17]. For biological 
applications, the size of nanomaterials usually ranges from 5 to 250 nm [18]. Some researchers 
and organizations such as FDA classify particles under 1000 nm as nanomaterials in 
pharmaceutical sciences [19-21].  
The word nano is derived from a greek word “nanos” meaning dwarf and represents 10-9 of 
the accompanying suffix unit. The concept of nanotechnology was coined in 1959 by Nobel 
laureate Richard P. Feymann in his talk entitled “There is plenty of room at the bottom” [22]. 
Nanotechnology is emerging as a promising field in biological sciences as numerous vital 
components of the cellular machinery such as DNA, RNA, antibodies, enzymes, biochemical 
motors and molecule selective pumps fall within the nano-scale range as shown in Table 1.1. To 
probe these subcellular components and understand the processes occurring at this scale, probing 
machineries and tools should have comparable size ranges. 
Particles acquire unique characteristics at the nano-level. Nanomaterials possess a large 
surface area to volume ratio, leading to an increase in their reactivity compared to micro and 
macro particles. There is a dominance of quantum effects at the nano-size, which affects their 
optical, electrical, thermal and magnetic behavior [23]. For example, gold particles differ 
considerably in their color, melting point and catalytic effects depending upon their size [24]. 
Other materials showing different characteristics at macro- and nano-scale level are listed in 
Table 1.2 [24].   
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Table 1.1: Various cellular machineries along with their typical sizes 
 
 
 
Cellular component Size (nm) Reference 
DNA (diameter) 2.5 [25] 
Ribosome 20 [26] 
tRNA length 10 [26] 
ATP biochemical motor 10 [25] 
Actin 10 [26] 
Chymotrypsin 4.0 [26] 
Hemoglobin 6.4 [27] 
Width of cell membrane 6-10 [28] 
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Table 1.2: Size-dependent differences in physical properties of materials  
Material Macro-scale level Nano-scale level 
Copper Opaque Transparent 
Platinum Inert Catalyst 
Aluminum Stable Combustible 
Silicon Insulator Conductor 
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 Overview of Gene Therapy and its Barriers 1.2
Gene therapy deals with the treatment of inherited and acquired human diseases by 
inserting or replacing the missing or defective genes into the cell. Candidate diseases for gene 
therapy include hemophilia, liver hypercholesterolemia, cystic fibrosis, thalassemia, sickle-cell 
anemia, cancer, neurological, cardiovascular and infectious disorders [11]. Two main approaches 
for achieving gene therapy include induction of desired gene expression and modulation of the 
undesired gene expression. While the gene expression can be induced in cells by using 
therapeutic DNA encoding for the missing or defective genes, the silencing is achieved by using 
double stranded RNAs, small interfering RNAs (siRNA) and antisense 
oligodeoxyribonucleotides complementary to the targeted mRNA. DNA and siRNA differ in 
their site of action: generally, the DNA needs to be delivered into the nucleus of the cells to 
produce the desired gene expression, whereas the siRNA has to travel only to the cytoplasm to 
induce gene silencing [29] by degrading the mRNA possessing complementarity to its antisense 
strand [30].  
The major obstacle to the use of naked nucleic acids as therapeutics is their inefficient 
cellular delivery. Physiochemical characteristics such as highly negative surface charge and large 
molecular weight are barriers in the efficient cellular internalization of the DNA [29,31] and 
siRNA [32,33]. In addition, the naked siRNA also triggers the immunogenic response when 
administered systemically [34,35]. While the DNA is extremely large for the efficient cellular 
uptake, the small size of siRNA also pose an additional challenge to its effective cellular delivery 
[36] as the particles having molecular weight less than 50 kDa are susceptible to excretion 
through glomerular filtration [32]. Intravenously administered naked siRNA having 21-23 base 
pairs (~13 kDa) accumulate in kidneys and experience rapid renal clearance [37,38]. Therefore, 
it is of paramount importance to increase the size of siRNA by complexing it with suitable 
nanocarriers to avoid its rapid excretion [36].  The scenario is different for plasmid DNA which 
contains several kilo basepairs; in this case, nanocarriers are required to condense the plasmid to 
a size range that can be internalized by the mammalian cells [29].  
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 Use of Nanocarriers in Gene Delivery 1.3
The success in gene therapy relies on complexing the genetic material with suitable 
nanocarriers. These carriers can be broadly classified under two categories: viral vectors and 
non-viral vectors.  
Viruses are natural machineries that have evolved to infect their hosts with high efficiency 
and exploit the cellular machinery of the infected cells for their own replication. The idea behind 
harnessing the viruses as gene delivery vectors capitalized on their highly infectious nature. 
Before using these biological machines to deliver the nucleic acids, their virulent genes are either 
deleted or inactivated [39], while preserving other useful regulatory sequences required for 
packaging and integration [13]. Moreover, the other viral coding sequences such as those 
involved in replication and producing capsid protein are also deleted from viral genome and are 
incorporated in a separate packaging construct [40]. This segregation of replication genes and 
non-coding viral sequences is essential to prevent the reversion of viral vector back to its 
pathogenic form [40]. The therapeutic genes are then introduced into the viral backbone to 
replace the deleted viral genes [13]. Some of the viral vectors utilized for delivering genetic 
material include retroviruses, adenoviruses, adeno-associated viruses and herpes simplex viruses 
[40].  
 Although viruses have high potential to invade the host cells, their application as gene 
delivery vectors is associated with many adverse effects. One of the most fatal consequences is 
the activation of the host’s cellular immune system that recognizes viral vectors as the 
pathogenic forms of virus [13]. The intravenous administration of the viral vectors suffers from 
cellular non-specificity and distribution, which can result in fatal consequences due to the 
massive immunogenic response [13]. In a clinical trial held in September 1999, systemic 
administration of a modified adenoviral vector led to disseminated vascular coagulation and 
consequently, multiorgan failure, leading to the death of a patient after four days of treatment 
[41]. In addition, the random integration of the viral vector genome into the chromosome of host 
cells can lead to insertional malignancies that have been evidenced by the development of 
leukemia in animal models [42,43] and humans (1 out of 4) [44].  In addition to packaging 
restrictions in the size of gene, it is difficult to produce clinical grade vectors at low cost 
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[13,45,46]. Therefore, the use of non-viral vectors is preferred over the viral systems as these 
have low immunogenicity, can accommodate any size nucleic acid, are lower in cost and are 
relatively safe [46,47].  
Among various non-viral vectors, detonation nanodiamonds (NDs) are emerging as a 
promising candidates for delivering genetic material into the mammalian cells due to their 
advantages such as narrow size distribution (4-5 nm), inert core, surface reactivity, low 
cytotoxicity, fluorescence, and potential to be characterized by Raman spectroscopy [15]. 
 Important Parameters of Nanoparticles 1.4
1.4.1 Cellular Delivery of Nanoparticles  
Macromolecules greater than 1 kDa cannot diffuse themselves through the cellular 
membrane [19], therefore their uptake is governed mainly by endocytosis. The endocytotic 
pathways can be classified into macropinocytosis (<1µm), clathrin-mediated endocytosis (~120 
nm), caveolae-mediated endocytosis (~60 nm), and clathrin- and caveolae- independent 
endocytosis (~90 nm) [48]. These pathways are responsible for the uptake of nanoparticles 
depending upon the size and other surface characteristics of the particles.[19] In the clathrin-
mediated endocytosis, the clathrin-coated pits invaginate and pinch off from the cellular 
membrane to form endocytic vesicles of 100-150 nm [49]. These vesicles, after uncoating [49], 
fuse with the sorting endosome (a type of primary endosome, with pH of 5.9 to 6.0),  mature into 
late endosomes (pH 5.0 to 6.0), and then transform into lysosomes (pH  5.0–5.5) [48]. In order to 
evade degradation due to the acidic pH in the lysosomes, the genetic material needs to be 
released from the primary endosomes. The nanoparticles are not transported to the lysosomal 
compartment when internalized by the caveolae-mediated endocytosis [50]. Therefore, the 
ultimate fate of particles is highly dependent upon their mode of internalization.  
Cationic nanoparticles such as polylysine, polyamidoamines, polyethyleneimine are 
suggested to be released from the endosomes by the “proton sponge” effect [31,51,52] and/or by 
endosomal membrane disruption [14]. The endosomal membrane is equipped with an ATPase 
proton pump that is responsible for an influx of protons into the endosomal lumen against the 
concentration gradient, creating the acidic environment [53,54]. Once trapped in the endosomes, 
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the cationic vectors with ionizable amine groups trigger the influx of H
+
 due to their buffering 
capacity, which is accompanied by the inflow of chloride ions (to maintain charge neutrality), 
and water [51,55]. As a consequence, the endosome undergoes osmotic lysis leading to release of 
nanoparticles into the cytoplasm. Although these cationic molecules have a potential of 
disrupting the endosomal membranes, the integrity of the cellular membrane might not 
compromised due to the pH differences [56,57].  
1.4.2 Characteristics of the Nucleic Acid Delivery Nanoparticles 
The physiochemical properties of nanoparticles such as size, zeta potential and 
aggregation have a substantial effect on the behavior of the nano-formulation in physiological 
systems. Therefore these parameters should be controlled and characterized critically.   
1.4.2.1 Size 
One of the strategies for effective cellular uptake and transfection is to control the particle 
size of the carrier and the carrier-nucleic acid complex. Systemic administration of the foreign 
particles causes activation of the human complement system that consequently leads to their 
rapid clearance from the circulation, predominantly when the particles are larger than 200 nm 
[58]. Alternatively, if the particles are too small, less than 5 nm, they will be cleared prematurely 
from the circulation via extravasation or renal route [19]. The size range between 100 to 300 nm 
for the nanocarrier-nucleic acid complex is suggested to have the highest potential for the 
efficient cellular interaction, uptake and endosomal release [12]. Although the size of caveolae 
pits range from 50 to 100 nm size [59], the internalization of latex beads of 500 nm was 
suggested to occur by this pathway [60]. Beads of less than 200 nm diameter were taken up by 
clathrin-mediated endocytosis in non-phagocytic cells [60]. Another study demonstrated a 
significantly higher gene expression by using larger polyplexes compared to the smaller sized in 
neuroblastoma and erythromyeloid cells [61]. Based upon the distribution profile of the particles 
in vivo, it has been suggested that the size range of rigid nanoparticle should be between 100 to 
200 nm [19]. 
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1.4.2.2 Surface Charge 
Genetic materials with highly anionic phosphate backbone when administered without 
delivery vehicle experience poor interaction with the negatively charged cell surface, resulting in 
poor cellular uptake and consequently poor gene expression [12,31]. Therefore, it is crucial to 
design carriers with the positive charges that can neutralize the negative charges of nucleic acids 
and facilitate their interaction with the cellular surfaces [31,62]. The positively charged carrier-
DNA complexes promote cellular endocytosis of the particles by altering the structural properties 
and ion permeability of the cell membrane [63]. The overall positive charge is an essential 
prerequisite for the effective cellular association of particles and their subsequent internalization 
[59]. 
In addition, the surface charge of the particle also determine the colloidal stability of the 
dispersion and can be predicted by measuring the zeta potential of the system [64]. According to 
the conventional Derjaguin-Landau-Verwey-Overbeek (DLVO) theory, the interaction between 
two particles is the sum of the electrostatic repulsion and the van der Waals attraction [65]. Since 
the behavior of nano-scale particles in the liquid medium is strongly dominated by the inter-
particle forces [66], in order to achieve stable dispersion, one should consider generating like-
charged surfaces that could provide sufficient electrostatic repulsion between the particles to 
maintain their dispersion stability [66]. Dispersions with zeta potential below a critical value of 
20-30 mV are considered to be relatively unstable and tend to coagulate easily [67]. 
However, caution should be taken while designing the formulation since an excess of 
positive charge can induce toxic effects by disrupting the cellular membrane [18,68]. 
Nanotechnology Characterization Laboratory, Frederick, MD indicated a positive relationship 
between the zeta potential and the cytotoxic effects [69]. A study compared anionic and cationic 
charges on the gold nanoparticles and found that the cationic particles possess a  relatively higher 
cytotoxicity [70]. Similar results were observed by using cationic polystyrene nanospheres in 
vitro and in vivo [71]. Therefore, an optimal positive charge on the particle is desired that should 
favor colloidal stability and interaction with cellular membrane without inducing cytotoxicity. 
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1.4.2.3 Aggregation  
As the surface area to volume ratio of the particles increases with the decrease in the size, 
the Van der Waals forces along with electrostatic interactions and chemical bonding  dominate 
[7], leading to a significant aggregation of nanoparticles [72]. Systemic administration of 
aggregating nanoparticles can result in the occlusion of the blood flow in the blood vessels, 
causing severe embolism [7,27]. Aggregated particles could also accumulate in various organs of 
the body, leading to severe consequences such as pulmonary embolism, myocardial infarction, 
stroke and microinfarction [27]. Furthermore, agglomeration can also initiate an immune 
response [7]. Aggregated carbon nanotubes have shown higher in vitro toxic effects compared to 
their dispersed state [73]. Aggregation of nanoparticles may adversely affect their interactions 
with the cellular membranes to ultimately influence the cellular uptake [8,74], although the effect 
is not yet clear [75].  
Maintaining nano-scale particle size necessitates the use of mechanochemical treatment 
that not only leads to disaggregation but also prevents the re-aggregation of particles. Mechanical 
treatment such as sonication can break the aggregates without affecting the surface properties of 
particles, and then chemical functionalization can sterically and/or electrostatically stabilize the 
dispersion [72]. Therefore, mechanochemical treatment has a potential to reduce the size of 
aggregated particles and maintain their dispersion stability. 
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                                                                                                               Chapter 2
NANODIAMONDS AS NOVEL NANOMATERIALS FOR BIOMEDICAL 
APPLICATIONS- DRUG DELIVERY AND IMAGING SYSTEMS  
Kaur R, Badea I. International Journal of Nanomedicine.2012;1(7): In Press 
Abstract    
Detonation nanodiamonds (NDs) are emerging as delivery vehicles for small chemical 
drugs and macromolecular biotechnology products due to their 4 to 5 nm primary particle size, 
stable inert core, reactive surface and ability to form hydrogels. Nanoprobe technology 
capitalizes on the intrinsic fluorescence, high refractive index and a unique Raman signal of the 
NDs, rendering them attractive for in vitro and in vivo imaging applications. This review 
provides a brief introduction of the various types of NDs and describes the development of 
procedures that have led to stable single-digit-sized ND dispersions, a crucial feature for drug 
delivery systems and nanoprobes. Various approaches used for functionalizing the surface of 
NDs are highlighted along with a discussion on their biocompatibility status. The utilization of 
NDs to provide sustained release and improve dispersion of hydrophobic molecules, of which 
chemotherapeutic drugs are the most investigated, is described. The prospects of improving the 
intracellular delivery of nucleic acids by using NDs as a platform are exemplified. 
Photoluminescent and optical scattering properties of NDs together with their applications in 
cellular labeling are reviewed. Considering the progress that has been made in understanding the 
properties of NDs, they can be envisioned as highly efficient drug delivery and imaging 
biomaterials for animals and humans.  
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 Introduction 2.1
Elemental carbon has six electrons with an electronic configuration of 1s
2
 2s
2
 2p
2
 in its 
ground state. The two electrons of the 1s orbital are core electrons, while the other four are 
valence electrons. The sp
2
 hybridization of carbon atoms leads to the formation of the two-
dimensional planar hexagonal structure of graphite.  In this type of arrangement, the central 
carbon is linked to three other carbon atoms by σ-bonds with the remaining electron of the pz-
orbital forming a delocalized cloud of π electrons over the graphitic structure. The sp3 
hybridization of carbon atoms forms a rigid diamond structure with tetrahedral symmetry, where 
all the four valence electrons of the carbon atom each form an σ bond with the neighboring 
carbon atoms. The general lack of free electrons in the bulk structure of diamond accounts for 
their inertness. However, the surface structure of the material is different from the bulk, due to 
the relaxation at the surface and the need to terminate the bonds. Thus, the terminating structure 
on diamond surfaces involves univalent species such as H or OH or any deliberate terminating 
groups for both nano- and larger gem diamonds (synthetic and natural).  
Nanodiamonds (NDs) have attracted a great deal of scientific and technological interest 
due to their unique structural, chemical, biological, mechanical and optical properties. Based 
upon their primary particle sizes, Shenderova and McGuire classified NDs into nanocrystalline 
particles (1 to ≥150 nm), ultrananocrystalline particles (2 to 10 nm) and diamondoids (1 to 2 nm) 
[1]. The ultrananocrystalline diamond particles are of particular interest for biomedical 
applications and focus has been largely placed on detonation NDs with primary particle size of 4 
to 5 nm [2].  
Figure 2.1 shows the classification of diamonds based on synthetic production methods. 
These include chemical vapor deposition diamonds, high-pressure high-temperature diamonds 
and detonation NDs. 
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Figure 2.1: A schematic representation of types of nanodiamonds based upon their 
synthesis procedures and applications. 
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 Deposition of carbon vapors on a diamond or non-diamond substrate leads to the 
formation of diamond films [3], of which nanocrystalline and ultrananocrystalline types are of 
major interest, due to their superior mechanical and wear resistant properties. Depending on the 
growth precursors (hydrogen-rich and carbon-poor precursors) and other deposition parameters 
such as biasing voltage, surface temperature and film pressure, the grain size of nanocrystalline 
diamond films can vary from 5 to 100 nm [4,5]. The ultrananocrystalline diamond films, with a 
much smaller grain size of 3 to 5 nm are usually synthesized under hydrogen-poor and argon-
rich conditions [6-8]. In addition to the difference in grain size, these two types of diamond films 
also differ in the sp
2
 carbon content. The nanocrystalline diamond films grown in a methane-rich 
environment possess up to 50% sp
2
- bonded carbon structure, which decreases drastically to less 
than 0.1% with the decrease in the amount of methane [9]. For the ultrananocrystalline diamond 
films, the sp
2
- bonded carbon fraction ranges from 2 to 5% [9]. Scanning transmission electron 
microscopic images of nanocrystalline [4] and ultrananocrystalline [10] diamond films are 
shown in Figure 2.2.  
The ultrananocrystalline diamond films are emerging as superior substrates to that of 
silicon, platinum and quartz for coating biomedical implants [11,12]. This advantage is due to 
their low cytotoxicity, dense structure, high surface roughness, sp
2
 structural boundaries and 
surface dangling bonds [11,12]. These films also exhibit desired characteristics for producing 
micro-electro-mechanical devices due to their robustness, high Young's modulus, high acoustic 
velocity, high resistance to fracture and low coefficient of friction (∼0.01–0.1) [13-16]. 
Similarly, high stability, superior electrochemical properties, selectivity in binding biological 
materials and biocompatibility of the nanocrystalline diamond films have opened up their 
potential in the development of biosensors [17,18].  
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Figure 2.2: Scanning electron microscopic image of nanocrystalline and 
ultrananocrystalline diamond film. 
 
Scanning electron microscopic image of (A) nanocrystalline [4] and (B) ultrananocrystalline [10] 
diamond film grown on silicon substrate. “Reprinted (A) with permission from [4]. Copyright 
(2003), American Institute of Physics.” “Reprinted (B) with permission from [10]. Copyright 
(2007) by the American Physical Society.” 
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Synthetic diamonds produced by a high-pressure high-temperature technique could 
contain 100 to 300 ppm of nitrogen [19-22]. High energy irradiation of these diamond particles 
causes damage by knocking a diamond carbon atom out of the structure, creating vacancies (V) 
[23]. Upon thermal annealing, these vacancies move closer to the nitrogen (N) centers to form 
nitrogen-vacancy (N-V) color defect centers [23]. These centers are responsible for the emission 
of fluorescence [24]. Hence, high-pressure high-temperature synthetic diamonds have been 
widely explored as imaging agents in cellular models [19,22,25]. However, the high production 
cost and the general inability to produce diamond particles smaller than 20 nm are significant 
barriers to their use in biomedical sciences. 
The third category of diamonds, detonation NDs, also known as ultradispersed diamonds, 
are synthesized relatively inexpensively on a large scale by detonation of carbon explosives with 
a CmHnNoOp composition [26]. An overall negative oxygen balance of the explosive mixtures is 
required in the detonation chamber [26] to prevent the complete combustion of the carbon into 
its gaseous products. Generally, a mixture of trinitrotoluene and hexogen in a mass ratio ranging 
from 40:60 to 70:30 is utilized [27]. A shock wave produced by the detonator compresses and 
heats the composition mixture, leading to its explosion [26]. A large amount of energy is 
released during this exothermic process, which consequently raises the temperature in the 
detonation chamber to 3000-4000ºC and the pressure to 20-30 GPa, to favor the synthesis of the 
diamond particles (Figure 2.3) [28,29]. After the detonation is complete, a rapid cooling is 
achieved either by using an inert cooling gas (dry synthesis) or water (wet synthesis) [29].
 
The 
cooling of the detonation products is crucial to minimize transformation of the diamond phase 
into the graphitic forms, in accordance with the phase diagram (Figure 2.3) [28,29]. The average 
primary particle size of NDs generated by this technique is 4 to 5 nm (Figure 2.4) [28,30].  
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Figure 2.3: Pressure-Temperature phase diagram for carbon.  
 
Phase diagram for carbon depicting the (1) pressure and temperature requirements for synthesis 
of detonation nanodiamonds, and cooling profile of products produced by (2) wet detonation 
synthesis and (3) dry detonation synthesis [29]. "Reproduced courtesy of IOP Publishing Ltd".  
Note: TD represents Debye temperature. 
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Figure 2.4: High resolution transmission electron microscopic image of detonation 
nanodiamonds. 
 
Image is courtesy of Bogdan Palosz, IHPP, Warsaw, Poland 
  
 
   26 
  
 
Although the primary particle size of NDs obtained by the detonation technique is well 
suited for biomedical studies, the detonation products need to be extensively purified. Depending 
on the materials and matrices present during their production, detonation NDs can contain oxides 
and carbides, including those of iron, chromium, silicon, calcium, copper, potassium, titanium 
and sulfur, in addition to carbon soot [26]. To remove surface metallic impurities, NDs are 
treated with classic acidic treatments consisting of sulfuric acid, and its mixtures with nitric acid 
or potassium dichromate [31]. A hydrofluoric acid and nitric acid combination has also been 
used to eliminate metallic contaminants from the particles [32]. The oxidization and subsequent 
removal of sp
2
- bonded carbon structures, present either in amorphous or graphitic forms, is 
achieved by the use of liquid oxidizers such as sodium peroxide, a chromium trioxide and 
sulfuric acid mixture, or a nitric acid and hydrogen peroxide mixture [31]. Thermal oxidation 
process, uses temperatures of 400 to 430ºC to allow the oxidation of sp
2
- bonded
 
carbon species 
in the air, with negligible alteration in sp
3
- bonded carbon structures [33]. These temperature 
requirements for the selective oxidation of sp
2
- bonded
 
carbon species were confirmed by Pichot 
et al [32]. The oxidation of NDs at a high temperature using air, containing ozone, is another 
approach that results in the removal of the majority of sp
2
- hybridized carbon structures [34]. The 
ozone-air treatment, also known as the gas phase treatment, is ecological and efficient as the 
purification of NDs is achieved without using the corrosive liquid oxidizers [34]. 
Although the size, shape and surface properties of NDs are determined by the nature of 
explosion and purification conditions, their basic structure follows a core and shell model [2].  
The diamond carbon forms the inert core and the surface shell is partially comprised of graphitic 
structures [30,35,36]. In addition, a wide variety of functional groups such as carboxyl, hydroxyl, 
lactone, anhydride, ketone and ether can be present on the surface of these ND particles [36,37]. 
The acid purification treatment increases the density of carboxylic and hydroxylic groups on the 
surface of NDs, resulting in their hydrophilicity.  
The economical large-scale production of detonation NDs provided considerable impetus 
to technological applications. For example, the antifriction properties of NDs and their soot make 
them ideal candidates as wear-protective additives [38].
 
 The stability of these particles at 
extreme temperatures may lead to their storage in liquid nitrogen and use in composite 
manufacturing [39]. The large surface area of NDs is suitable for adsorbing biomolecules, 
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presenting them as an attractive material for isolating proteins [40,41] and pathogenic 
microorganisms [42]. However, it was not until the identification and characterization of single-
digit-sized NDs in the dispersion medium that NDs were applied in biomedical sciences.  
 NDs in the Biomedical Field 2.2
The application of NDs in biological sciences requires the stable dispersion in a 
formulation medium, the ability to conjugate with biomolecules, an inherent biocompatibility 
and the ability to penetrate target tissues and cells.   
2.2.1 Dispersion of NDs 
Detonation NDs possess a strong propensity to aggregation when dispersed in a liquid 
formulation medium, hindering their biomedical applications. Several attempts to explain the 
aggregation phenomenon have focused on surface forces. The harsh conditions in the detonation 
chamber could create dangling bonds on the ND surfaces [43]. These free electron surfaces are 
sufficiently reactive to form functional groups, which then interact via various intermolecular 
surface forces such as van der Walls and dipole-dipole interactions, and hydrogen bonding [43]. 
In addition, these surface groups can also react to create covalent bonds between the primary 
particles, producing core aggregates [44]. Another study suggests that electrostatic forces 
induced by the oppositely charged facets of polyhedral shaped NDs are the primary cause for 
creating core aggregates [45]. This finding was supported later with the aid of electron 
microscopy and computer simulations [46]. Other than the surface forces, the “graphitic soot like 
structures” around the particles can also bind individual ND particles together into core 
aggregates (Figure 2.1) [35,36].  
Conventional techniques of disintegration such as milling, emulsification and low power 
sonication have been ineffective in breaking down the tightly bound core aggregates of NDs to 
less than 10 nm [35]. Therefore, in an attempt to achieve primary-sized NDs, milling was carried 
out using an excessive amount of 100-µm silica beads [35]. Single-digit-sized NDs were 
obtained after an hour of sonication of the diluted milled suspension and the stability of the 
resulting aqueous colloid was maintained for a year [35]. However, reconstitution with water 
after drying the nanodispersion resulted in reaggregation with 2.3 µm size aggregates [35]. Bead-
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assisted sonic disintegration using zirconia beads has also gained interest for breaking the ND 
aggregates in aqueous medium to single-digit-sized particles [47]. This mechanical technique 
involves the combination of shear forces induced by beads with their acceleration during 
cavitation created by intense ultrasonic waves. These primary sized NDs exhibited very good 
colloidal stability in polar solvents such as water and DMSO [47]. However, contamination from 
the beads [35] and sonotrode material itself can be a barrier for these technologies [45,48] in 
addition to the structural alterations [49].  
Bead-assisted milling [47,50] or sonication [48] yielded clear, but dark brown 
nanodispersions of diamond particles.  It should be noted that sonication creates microbubbles in 
liquid media, which implode violently, generating a local temperature of ~1900 K at the bubble-
liquid interface [51]. The shock waves produced during high power sonication cause high-speed 
collision of the beads with ND particles, which can lead to the conversion of the diamond carbon 
into its graphitic form, according to the diamond-graphitic phase transition phenomenon 
occurring at temperatures greater than 1200 K [52]. Similarly, a temperature of 1800 K can be 
attained during milling collisions when the speed of the blades is between 0.1 to 10 cm/s [49,50]. 
This could explain the black coloration of the colloids observed after high speed milling or high-
power bead-assisted probe sonication. 
Mechanochemical treatment, which involves the breaking of ND aggregates by 
mechanical energy and the concurrent loading of electrolytes or surfactants on a newly created 
surface, was also explored to achieve stable dispersions with a noticeable size reduction [53]. 
However, a primary dispersed particle size of less than 10 nm was not achieved [53]. 
Ultracentrifugation, a contamination-free  procedure, resulted in 4 nm size NDs that formed a 
stable colloidal dispersion in water [54]. The yield of single-digit-sized particles was only 1% 
after centrifugation of the ND suspension at an acceleration of 2.80 x 10
5 
g for 40 minutes [54]. 
Increasing the centrifugation time to 240 hours at an acceleration of 2.0 x10
4 
g did not improve 
the yield significantly, generating 6% of NDs with an average size of 8 nm [54]. Hence there is 
still a need for development of easy, feasible, contamination-free techniques that can result in 
disaggregation of NDs at the laboratory scale.  
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2.2.2 Surface Modification of NDs   
All together, the nano-size, the larger surface area, and potential for purification with 
oxidizing agents, make NDs a viable candidate for surface functionalization. Figure 2.5 
summarizes approaches used in the past to introduce various functionalities on the surface of 
NDs [44,55-61]. One of the earliest modifications of the ND surface involved the generation of 
surface radicals, which then acted as substrates for synthesizing carboxylic [55] and dicarboxylic 
acid [56] functionalized NDs. For a high surface loading, it is essential to achieve surface 
uniformity. Reactions with hydrogen [55,56], chlorine [57], and fluorine [58] have been explored 
to attain surface homogeneity as well as reactivity enhancement. The surfaces of chlorinated 
NDs were further modified with hydroxyl, amine and carbon fluoride groups [57]. Finally, 
reactions of NDs with alkyllithium, ethylenediamine and glycine ethyl ester hydrochloride 
generated alkyl, amino and glycine substituted NDs, respectively [58].  
Surface functionalization has also emerged as a novel treatment for reducing aggregate 
sizes of NDs. Functionalization with long alkyl chains reduced the particle size from 15 µm to 
150-450 nm [59]. The long alkyl chain-modified NDs showed an enhanced dispersibility in 
organic solvents compared to their pristine form [59].  Similarly, surface modification with 
fluorine contributed to size reduction from 1930 to 160 nm [58]. A noticeable size reduction of 
the micrometer-sized pristine NDs to ~ 50 nm was also achieved upon reduction of the ND 
surface groups with borane, which, after being grafted with alkyl silane, were used to synthesize 
biotinylated NDs with a surface loading of 1.45 mmol/g [61].  
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Figure 2.5: A schematic representation of approaches used for modification of 
nanodiamond surfaces. 
 
Abbreviations: Abs, Absolute; R.T., Room temperature; R, alkyl group; Ar, aromatic group; 
THF, tetrahydrofuran; DMAP, (dimethylamino)pyridine; EDC, (1-ethyl-3-[(3-dimethyl 
amino)propyl] carbodiimidehydrochloride) 
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2.2.3 Biocompatibility Studies of NDs 
The intrinsic biocompatibility of detonation NDs has been supported by the results of a 
number of studies [62-67], however, some studies have refuted this claim by arguing that NDs 
can induce toxic responses under certain conditions [68,69].  
Biocompatibility of 2 to10 nm sized acid- or base-purified NDs was first demonstrated in 
neuroblastoma, macrophages, keratinocytes and PC-12 cells [62]. By considering the 
mitochondrial activity as a key determinant of cellular viability,  NDs up to a concentration of 
100 µg/mL were reported not to be cytotoxic over a 24 hour incubation period [62]. In addition, 
NDs showed higher biocompatibility than carbon black, and single and multi-walled carbon 
nanotubes [62,63]. When incubated for 24 hours with NDs at the concentration range of 25 to 
100 µg/mL, no significant cell death occurred in neuroblastoma cells [63]. Similarly, alveolar 
macrophages maintained the cellular viability upon exposure to 25 µg/mL concentration of NDs 
for 24 hours [63]. In addition to mitochondrial function, the inflammatory activity of cells has 
also been a key determinant of the toxic effects of nanomaterials [67]. There was no significant 
increase in the gene expression of inflammation biomarkers, such as interleukin-6, tumor 
necrosis factor-alpha and nitric oxide synthase, in murine macrophages after incubation with a 
100 µg/mL concentration of NDs [67].  In addition, no attenuation in the gene expression level 
of Bcl-x, which generally diminishes with an increased risk of apoptosis, endorsed the intrinsic 
biocompatibility of these diamond nanoparticles [67]. 
Various studies have demonstrated that the toxicity of NDs can vary depending upon 
their surface chemistry [69,70], type of cell line [69] and the treatment medium [68] 
composition. The amine terminated NDs exhibited a higher toxicity (~22% cell death) than 
hydroxyl (~11%) and carboxyl group (~7%) terminated NDs in human embryonic kidney cells at 
a concentration of up to 200 µg/mL [70]. The carboxylated NDs did not show any significant 
genotoxic effects in mouse embryonic fibroblasts [71], but induced DNA damage in mouse 
embryonic stem cells [69], although to a lesser extent than that occurred with multi-walled 
carbon nanotubes [72]. In another instance, a 100% viability of human cervical cancer (Hela) 
cells was observed after incubating them with 0.1-100 µg/mL NDs in a medium containing 
serum for 24 hours [68]. In the absence of serum, this viability dropped dramatically to almost 
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0% within 6 hours of dosage with 50 µg/mL NDs [68].  A similar behavior has been also 
observed with other nanoparticles such as carbon black [73] and silica [74]. Although there is no 
clear explanation of serum-dependent cytotoxicity of nanoparticles so far, several hypotheses 
have been put forth. It is believed that serum can have a protective effect on the cells by coating 
the surface of nanoparticles that are thought to have inherent cytotoxic effects [68,73,75]. While 
on the one hand, serum is found to enhance the dispersion stability of the nanoparticles 
[68,73,76], on the other hand, serum promotes aggregation [74]. The cellular internalization of 
nanoparticles was observed to be higher in the absence of serum than in its presence [73,74], 
which might be one of the reasons for the lower cellular toxicity of nanoparticles when incubated 
with serum. Another study found that nanoparticles could adsorb the essential micronutrients 
from the medium and hence indirectly produce cytotoxic effects by depleting the cellular 
structures of essential nutrients [77]. Finally, the serum proteins themselves are essential for the 
growth of the cell, thus their absence can have a negative effect on overall cell proliferation. 
However, it is important to note that in some studies, NDs did not show significant toxicity, even 
when incubated with cells in medium lacking serum [62,63]. 
In addition to the cellular studies, some in vivo studies have also been conducted to 
evaluate the toxicity of NDs. Intravenous administration of 125 mg of modified NDs did not 
cause any death in rabbits [78]. Neither the red blood cell count nor the hemoglobin level of 
rabbits decreased after 15 minutes of administering 50 mg of modified NDs, intravenously [78]. 
However, after 48 hours of injection, the levels of biochemical molecules such as total bilirubin, 
triglyceride, low density lipoproteins, aspartate aminotransferase and γ-glutamyltranspeptidase 
altered significantly [78]. In another study, an oral administration of 0.002 to 0.05 wt.% of ND 
hydrosols to mice, in place of water, for 6 months showed no significant abnormalities in growth 
or organs weight [39]. The NDs exhibited low pulmonary toxicity and were cleared from the 
lungs after 90 days of intratracheal instillation in ICR strain mice [79]. Furthermore, the 
clearance of XenoFluor 750 labeled NDs from all the body organs of wild type FVB/N mice 
occurred in 3 to 10 days after tail vein injection at a dose of 120 µg [80].  
In summary, NDs have shown biocompatibility in various cell lines and some animal 
models with minimal or no cytotoxicity, demonstrating their potential for biomedical 
applications. However the purity, surface chemistry and dimensions of particles should be 
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considered carefully. More comprehensive and long term animal studies need to be conducted to 
verify the safety of NDs before proceeding to human clinical trials. 
2.2.4 Cellular Uptake of NDs  
A number of studies have demonstrated the ability of NDs to internalize into cells 
[19,25,62,64-66,81-83]. Faklaris et al demonstrated that NDs having an average size of 46 nm 
internalize into Hela cells predominantly by clathrin-mediated endocytosis after 2 hours of 
incubation [83]. In addition to the clathrin-mediated endocytic pathways, 100 nm sized NDs 
were also found to be internalized via macropinocytosis by cancer and stem cells after 4 hours of 
incubation [71]. The intracellular localization of the NDs suggests that these nanoparticles have a 
potential to be employed for the intracellular delivery of therapeutic molecules. While the NDs 
used in these studies showed only perinuclear localization with no translocation to the nucleus 
[71,83], fenton-treated NDs were detected in the nucleus of Hela cells [84]. The internalization 
of NDs into cells could be dependent upon their surface characteristics [84], incubation time 
period, and other physiochemical parameters such as size, shape, aggregation etc. Nuclear 
internalization of NDs opens up perspectives for their use as delivery agents for nucleic acids. 
Figure 2.6 summarizes the prominent applications of NDs in the biomedical field. 
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Figure 2.6: A schematic representation of the applications of nanodiamonds. 
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 Applications of NDs as Drug Delivery Agents 2.3
The large surface area of biocompatible NDs having several surface functionalities is 
ideal for conjugating various biochemical entities. The suitability of the carrier can be projected 
from its loading capacity as well as from its ability to protect and retain the inherent therapeutic 
effects of the attached entities. A high loading capacity allows a high concentration of payload to 
be delivered while using a lesser amount of delivery agent itself. In parallel to the loading 
capacity, the release of payload from the carrier is also important. The feasibility to tune the 
release of cargo from the carrier is advantageous in developing novel applications of these 
delivery agents, such as controlled and sustained release delivery. Diamond nanoparticles are 
being investigated globally for improving the intracellular delivery of small molecules and 
biotechnological products, with a major focus on chemotherapeutic agents. Although some 
studies have made use of the ND surfaces to bind drugs via chemical bonding,[85,86] the 
majority have focused on physical adsorption procedures [67,68,80,87]. This simple process of 
loading cargo onto the carrier via physical interactions avoids the use of complex chemical 
reactions, which in addition to high cost, can also affect the therapeutic activity of the attached 
entity by causing structural alterations [88].  
The use of NDs as a small molecule delivery agent, using chemotherapeutic drugs as 
model drugs, has been exemplified by various studies. 
2.3.1 Delivery of Small Molecules    
In 2007, the suitability of NDs to act as a delivery agent of doxorubicin hydrochloride 
(DOX) was evaluated [67]. The investigation was based on the rationale that the surface 
carboxylic and hydroxylic groups of detonation NDs can interact efficiently with the amine 
groups of DOX via ionic forces when dispersed in aqueous medium [67]. The surface loading of 
DOX on NDs increased from 0.5 to 10 wt.% upon addition of 1% sodium chloride solution to 
their aqueous dispersion, and the removal of salt favored the release of DOX [67]. NDs loaded 
with DOX were suggested to assemble in the form of loose clusters, such that a certain amount 
of DOX adsorbed on the NDs surface resides within the cavity of the cluster (Figure 2.7A) [67]. 
This strategy of drug entrapment in loose aggregates of NDs could provide an advantage by 
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minimizing the systemic adverse effects of the naked DOX [67]. Thus, ND-based delivery 
systems could overcome the limitation to the use of high concentrations of chemotherapeutic 
drugs [89] in cancer treatments. In addition, the lower cytotoxicity of the ND-DOX composite in 
mouse macrophages and human colorectal cancer cells compared to bare DOX in a 48 hour 
period could be beneficial in sustained drug release [67].  
Another study, published in 2010, proposed NDs as efficient multifunctional delivery 
agents for the chemotherapeutic drug, 10-hydroxycamptothecin (HCPT) [68]. Similar to the 
previous study by Huang et al [67], NDs were able to adsorb the drug onto their surfaces via 
simple physical forces [68]. However in this case, the surface loading of HCPT was considerably 
enhanced to 50 wt.% from 0.4 wt.% with an increase in pH of the HCPT solution from 7 to 8.2, 
rather than by means of salination [68]. NDs released HCPT slowly into the PBS medium over a 
period of 5 days, with only 38% release observed in the first 24 hours [68]. In addition, the ND-
HCPT complex showed almost 2.5 times higher cytotoxicity in Hela cells compared to the 
chemotherapeutic activity of HCPT alone, credited to the ND triggered intracellular delivery of 
HCPT [68]. Bovine serum albumin adsorbed on the surface of NDs rapidly (< 1 hour) while 
HCPT showed a gradual adsorption (> 120 hours) [68]. Based on this differential adsorption, a 
model suggesting porous clusters of NDs was developed in which small molecules diffuse inside 
the clusters (Figure 2.7A) and the large molecules adsorb only on the outer surface of NDs 
(Figure 2.7B) [68]. Hence, NDs can facilitate the intracellular delivery of both small molecule 
drugs and large therapeutic biomolecules.  
Detonation NDs have also been utilized to increase the aqueous dispersibility of 
hydrophobic drugs. Poorly-water soluble chemotherapeutic drugs such as, Purvalanol A with 
therapeutic activity against liver cancer [90], and 4-hydroxytamoxifen with a high potential to 
treat breast cancer [91,92], are soluble in the polar, organic solvents DMSO and ethanol, 
respectively [87]. The use of non-aqueous solvents limits the parenteral administration of these 
formulations in clinically relevant settings. However, when formulated with NDs, the aqueous 
dispersibility of Purvalanol A and 4-hydroxytamoxifen  enhanced markedly [87]. By adsorbing 
the drug on their surfaces, NDs considerably reduced particle size and increased the zeta 
potential of these drugs in water, promoting their dispersibility and, potentially, cellular uptake 
[87]. Similar to the previous studies, NDs preserved the therapeutic activity of the drugs as 
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demonstrated by DNA fragmentation and MTT assay for ND-4-hydroxytamoxifen and ND-
Purvalanol A composites, respectively [87]. These findings suggest that NDs could play an 
important role in designing injectable formulations of water insoluble drugs.  
The efficacy of NDs to deliver chemotherapeutic drugs was examined recently in animal 
models for the first time [80]. In addition to generalized toxicity, large particle size and poor 
water solubility, chemotherapeutic drugs also suffer from acquired and intrinsic chemoresistance 
of tumor cells [93]. Among various other factors, overexpression of P-glycoprotein on the 
cellular membranes, causing premature efflux of the drug from cells, is the leading cause in 
developing chemoresistance in mammalian tumor cells [94,95]. This challenge could be 
addressed by using a delivery system that not only enhances the uptake of the chemotherapeutic 
drugs but also retains them in the cancer cells for a longer period of time. The study revealed that 
DOX bound to the ND surface was significantly more toxic towards DOX resistant mouse LT2-
Myc liver and 4T1 mammary tumor models compared to bare DOX [80]. The high 
chemotherapeutic efficacy of the ND-DOX composite was attributed to ND mediated DOX 
retention in tumors cells as determined by fluorescence microscopy and quantitative analysis 
[80]. Moreover, long term treatment showed superiority of the DOX bound to ND over the bare 
DOX in preventing tumor growth [80]. NDs not only circumvented the premature efflux of DOX 
from tumor cells, but also improved the adverse effects of naked DOX, by significantly reducing 
myelosuppression and early mortality [80]. In addition, NDs increased the circulation half time 
of DOX from 0.83 to 8.43 hours [80], which further validated their sequestering behavior, which 
was proposed in earlier studies [67,68]. 
In summary, formulation of chemotherapeutic drugs with NDs improves the 
pharmaceutical properties of the agents by high surface loading, improved aqueous dispersibility, 
sustained release, and enhanced retention in chemo-resistant cells. These properties are due to 
the hydrophilic functional group-enriched surface, large surface to volume ratio, ability to form 
loose clusters, improved cellular delivery, and biocompatibility of the NDs. Hence, NDs are 
suitable platforms to build nanoparticles for overcoming some of the major deficiencies of the 
chemotherapeutic drugs.  
In addition to small molecules, NDs have also shown potential as delivery agents for 
protein, DNA and RNA. 
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2.3.2 Delivery of Biotechnology Products 
The potential of NDs as a targeted protein delivery vehicle was evaluated in a pH-
dependent system [96]. By means of physical adsorption, NDs achieved a considerably high 
surface loading of bovine insulin (∼80%) in pH-neutral water at a weight ratio of 1:4 of 
insulin:ND [96]. Similar to a previous study [87], the physiochemical properties of the insulin, 
including size, zeta potential and polydispersity index, improved after interacting with NDs [96]. 
It suggests that NDs have the ability to facilitate uniform sized complex formation [96]. Further, 
the release of insulin from the surface of NDs was almost 20 times higher at a pH of 10.5 as 
compared to that obtained in neutral pH medium [96]. The applicability of ND-bound-insulin 
was verified by MTT assay in serum-starved murine macrophages [96].  A higher cellular 
viability was observed with sodium hydroxide treated ND-insulin in comparison to neutral pH 
treated ND-insulin [96]. Similar results were obtained by measuring the gene expression of 
Insulin 1 and granulocyte colony stimulating factor in serum starved mouse adipocytes [96]. 
Hence, formulations of  insulin can be designed with NDs to target the recovery of injured 
tissues [97] that have a basic pH due to bacterial growth [96,98]. 
Although there is compelling evidence to support the utilization of NDs as drug delivery 
agents for small molecules, their potential as gene delivery vectors has been less widely 
explored. The major obstacle to the use of naked nucleic acids as therapeutics is their inefficient 
cellular delivery. Physicochemical characteristics such as high negative surface charge and large 
molecular weight are barriers in the efficient cellular internalization of the DNA [99,100] and 
siRNA [101,102]. While DNA is too large for cellular uptake, the relatively small size of siRNA 
also poses an additional challenge to its cellular delivery, as particles having a molecular weight 
less than 50 kDa are susceptible to excretion through glomerular filtration [101,103].  Zhang et 
al, investigated NDs as a platform to build enhanced plasmid DNA delivery systems (Figure 
2.7C) [104]. At first, they coated NDs with polyethyleneimine 800 (PEI800), and then allowed 
them to interact with luciferase plasmid DNA via electrostatic forces [104].  NDs were found to 
enhance the transfection efficiency of the polymer by 70 fold at a 15:1 weight ratio of ND-
PEI800:pDNA in Hela cells, which might be due to ND mediated cellular and nuclear uptake of 
the plasmid DNA [104]. Similar to DNA delivery, the ND-based complex (ND-PEI800) was 
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used to deliver anti-green fluorescent protein-small interfering RNA (siRNA) to breast cancer 
cells expressing green fluorescent protein (Figure 2.7D) [105]. Compared to the PEI:siRNA, the 
ND-PEI800:siRNA complex at a weight ratio of 3:1 showed almost two fold higher knockdown 
in cellular green fluorescent protein expression [105]. In the presence of serum in the treatment 
medium, ND PEI800:siRNA complex showed better knockdown in green fluorescent protein 
expression as well as lower cytotoxicity than Lipofectamine that is a gold standard for in vitro 
delivery of nucleic acids [105]. Therefore, NDs have potential to enhance the transfection ability 
of polymers while remaining biocompatible to the cell lines. 
 However, there are limited studies of the applications of NDs as drug delivery agents so 
far. More studies are needed to verify their potential and to translate their use as a delivery agent 
into clinical applications.  
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Figure 2.7: A schematic representation of the binding behavior of nanodiamonds with 
different biomolecules.  
 
A schematic diagram to represent the binding of detonation nanodiamonds with (a) small 
molecules [67,68], (b) proteins [68], (c) plasmid DNA [104] and (d) siRNA [105]. 
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 NDs as Bioimaging Agents 2.4
2.4.1 Fluorescence of the NDs 
Based upon the presence or lack of nitrogen impurities in the crystal lattice structure, the 
natural diamonds are classified as type I or type II, respectively [106]. The arrangement of 
nitrogen impurities is used to sub-classify type I diamonds into type Ia and type Ib [107]. While 
type Ib contains atomically dispersed single substitutional nitrogen impurities (C-centers), type 
Ia diamonds comprise an aggregated form of nitrogen [107]. The latter are categorized further 
into type IaA, having two aggregated nitrogen atoms (A-center), type IaB, having platelets and 
four aggregated nitrogen atoms surrounding the nearest lattice vacancy (B-center), and type 
IaA/B, possessing the characteristics of both type IaA and type IaB [107].  
Besides natural diamonds, synthetic diamonds manufactured under high-pressure high-
temperature conditions are also known to contain a high amount of nitrogen in the form of 
impurities [108]. The natural diamonds have mainly aggregated nitrogen defects (type Ia), while 
synthetic high-pressure high-temperature diamonds are predominantly embellished with single 
substitutional nitrogen centers (type Ib) [109]. Irradiation damage of type Ib diamond crystals 
creates intrinsic defects such as vacancies, which upon thermal annealing move towards nitrogen 
centers (N), and get trapped within to form nitrogen vacancy (N-V) color defect centers [23]. 
Generally, irradiation of these diamond particles is carried out by high energy electron (~2-MeV) 
[110-112] or proton (~3-MeV) [64,113] beam using Van de Graaff or tandem particle 
accelerators, respectively. These sources generate vacancies but are difficult to install in usual 
pharmaceutical or biomedical laboratory settings due to their high cost, complicated setup and 
safety issues [19]. Hence, to increase the feasibility of the production of fluorescent NDs on a 
wider scale, a moderate scale energy helium ion (40-keV) beam emanating from a radio 
frequency positive ion source was proposed [19].  Even though a much lower energy source was 
used in this irradiation process, none of the essential fluorescence spectral features were lost 
apart from a decrease in fluorescence intensity, when compared to the fluorescence spectra 
generated by 3-MeV energy proton beam irradiated particles [19]. This method not only 
benefited the laboratories having ordinary infrastructure in producing fluorescent NDs, but also 
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increased the yield of fluorescent NDs by creating a higher number of vacancies compared to 
electron and proton beam irradiated NDs [19,113,114]. 
Irradiated synthetic type Ib NDs, after 2 hours of annealing at 800°C, generated mainly 
two types of N-V defect centers, neutral nitrogen vacancy (N-V)
0
 with
 
zero phonon line at 575 
nm and negatively charged nitrogen vacancy (N-V)
-
 with
 
zero phonon line at 638 nm 
[19,83,111]. Among all the color centers, (N-V)
- 
dominate the fluorescence spectra of type Ib 
diamonds [23,112]. This defect center absorbs light photons at ~560 nm and fluoresces brightly 
at ~700 nm with a quantum efficiency close to 1 [115]. Therefore, these centers offer 
characteristically bright red fluorescence to diamond particles upon excitation with green-yellow 
light [22] and hence have found applications for high-pressure high-temperature NDs in imaging 
studies [19,25]. 
Extreme photostability of (N-V)
- 
defect centers [116,117] provides a greater advantage to 
NDs to emerge as an excellent candidate for long-term cellular imaging over commonly used 
fluorophores. The red fluorescent NDs (100 nm) remained stable with no observed 
photobleaching, upon continuous exposure to a 100 W lamp power for 480 minutes, whereas 
similarly sized red fluorescent polystyrene nanospheres photobleached within 30 minutes of 
photoexcitation [64]. In another instance, no photobleaching occurred in both 100 and 35 nm 
sized red fluorescent NDs when photoexcited with 8 kW/cm
2
 power density of light for 5 
minutes [25]. On the other hand, under the same photoexcitation conditions, the fluorescence of 
Alexa Fluor 546 conjugated to DNA faded completely in 12 seconds [25].  Additionally, the 
fluorescence of red NDs was found to be significantly brighter than that emitted by Alexa Fluor 
546 dye [25]. The evidence of photostability has also been determined for a 7 nm sized red 
fluorescent diamond nanocrystal that did not show any sign of photobleaching over a time period 
of 30 seconds [118]. In addition to resistance to photobleaching, the fluorescence of NDs (35 and 
100 nm in size) was also found to be immune to photoblinking on a time scale of 1 ms [25]. 
Moreover, due to the deep location of (N-V)
– 
centers in the lattice structure of NDs [119,120], 
the fluorescence remains unaffected by surface alterations, as evidenced by NDs functionalized 
with carboxylic acid [64], polylysine [25] and transferrin [121] groups. Therefore, the intrinsic 
photostablity of NDs opens avenues for carrying out chemical modification of their surface for 
specific imaging applications. 
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Furthermore, the red fluorescent NDs could also be more advantageous compared to 
organic fluorophores in obtaining bright contrast images in the cells. The absorption and 
emission wavelength of cellular endogenous components such as flavins, collagens, lipofuscins 
and coenzymes, ranging from 280 to 630 nm [122,123], coincides with most of the organic 
fluorophores used for cellular imaging [124]. Thus, it provides an undesirable, strong 
background to the fluorescence signal. However, the fluorescent NDs can act as an ideal 
candidate in this case as emission of the dominant color center of NDs, (N-V)
-
, occurs above 690 
nm [25,64], well separated from the cellular autofluorescence region. In addition, the average 
fluorescence lifetime of NDs is 17 ns [25,118], which is considerably longer than the lifetime of 
fluorescent organic dyes (<5 ns) and most of the cellular endogenous fluorophores (<6 ns) [122]. 
Hence, by applying time-gating [125] it is possible to collect the fluorescence of the NDs alone 
with minimal background cellular autofluorescence, thereby providing a high contrast imaging of 
NDs in the cells, which could not feasible with most of the commonly used organic fluorophores 
[25]. Table 2.1 lists the advantages of using red fluorescent NDs as a fluorescent tag for in vitro 
or in vivo tracking applications. 
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Table 2.1: Highlights of the unique fluorescence properties of nanodiamonds 
 
Properties Advantages 
High quantum efficiency Bright fluorescence 
Photostability over longer time periods Long term tracking of nanodiamonds in cells 
Emission wavelength >690 nm High contrast imaging of nanodiamonds 
Longer fluorescence lifetime High contrast imaging of nanodiamonds 
Deeper location of nitrogen vacancy centers 
No alteration in fluorescence due to surface 
modification 
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Similar to the N-V defect centers of type Ib synthetic diamonds, the nitrogen-vacancy-
nitrogen (N-V-N) or H3 defects centers [24,126] in natural type Ia diamond nanocrystals can be 
created by irradiating them with a high energy (3-MeV) proton or a medium energy (40-keV) 
helium ion beam followed by annealing at 800°C [82]. H3 defect centers have a zero phonon line 
at 503 nm, with absorption and fluorescence emission at 470 and 530 nm, respectively [22].
 
Therefore, type Ia NDs with H3 centers are known as green fluorescent NDs.  
Other than the natural and high-pressure high-temperature NDs containing nitrogen 
impurities, researchers are also trying to understand the fluorescence characteristics of detonation 
NDs. However, considering the actual composition of the explosive mixture (~20 mass% of 
nitrogen) used to synthesize these particles, they might contain a high concentration of nitrogen 
[127] either in their core structure or in the form of surface defects. At first, these nanoparticles 
were suggested to be devoid of C-centers and were believed to be unsuitable for imaging 
applications [21]. The absence of zero phonon lines corresponding to the nitrogen vacancy 
centers in irradiated and annealed detonation NDs suggested structural defects to be the origin of 
their fluorescence [128]. Z-contrast scanning transmission microscopy, high-resolution 
transmission electron microscopy and electron energy loss spectroscopy identified nitrogen in 
the core structure of detonation NDs [129].  Recently, Vlasov et al detected stable (N-V) color 
centers in detonation NDs having a size greater 30 nm after their irradiation and thermal 
annealing treatment [127]. While the occurrence of (N-V) color centers in the bulk structure of 
detonation NDs of less than 10 nm size has been questioned in various studies [130,131], Smith 
et al showed the presence of these centers in single-digit-sized irradiation damaged and annealed 
NDs [132]. Moreover, (N-V) color centers have also been discovered in non-irradiated, 5 nm 
sized detonation NDs [133]. The NDs synthesized by detonation technique are shown to possess 
up to 3 at.% of nitrogen impurities [127,134].   
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NDs, due to their bright fluorescence, high photostability with sufficiently long lifetime 
and excellent biocompatibility, are emerging as efficient and safe candidates for cellular 
imaging. 
In 2007, Fu et al explored the fluorescent properties of a single 100 nm red fluorescent 
ND to examine the binding pattern of negatively charged DNA with a positively charged ND 
[25]. Firstly, the molecules of T4 DNA labeled with TOTO-1 fluorophore were allowed to 
interact electrostatically with polyL-lysine coated carboxylated fluorescent NDs in a buffer [25]. 
The diluted solution containing a single fluorescent ND and DNA was then added into a 
microchannel of a coverglass plate terminated with amino groups, followed by DNA stretching 
using microchannel combing methodology [25]. After laser excitation of the sample at 514 nm, 
fluorescence was detected using a wide-field epifluorescence microscope equipped with 545 to 
605 nm and 675 to 685 nm wavelength channels [25]. By overlapping the fluorescence emitted 
from TOTO-1 dye and the ND, detected by the shorter wavelength channel, with that of ND 
alone, detected by the longer wavelength channel, it was discovered that the DNA interacts with 
the positively charged single ND through a wrapping arrangement (Figure 2.8) [25]. By using the 
fluorescence intensity of the ND as a control, it was observed that over a time period of 13.9 s, a 
35 nm ND travels within 1×1 µm
2
 area close to the nucleus of Hela cells [25]. To compare the 
photostability of TOTO-1 dye with fluorescent ND, samples were excited for 40 seconds at 514 
nm [25]. No sign of photobleaching was observed in the ND whereas the dye started fading 
within the first 5 seconds [25]. This study shows that a single fluorescent ND can function as 
tracking agent and probe to investigate the interaction between biomolecules.  
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Figure 2.8: Use of fluorescence of nanodiamonds in predicting DNA interaction with a 
positively charged nanodiamond.   
 
Overlay image (right) demonstrating the wrapping of TOTO-1 dye labeled T4DNA (green color, 
V-shape) around the surface of a single polyL-lysine coated fluorescent nanodiamond (red 
color). Reprinted with permission from [25]. "Copyright (2007) National Academy of Sciences, 
U.S.A." 
  
 
   48 
  
 
 In 2009, Weng et al investigated the uptake mechanism of transferrin in Hela cells using 
fluorescent properties of NDs as a biomolecule label [121]. They oxidized 100 nm red 
fluorescent NDs and conjugated transferrin to their surfaces through an amide linkage to form 
ND-transferrin conjugates [121]. These bioconjugates were then incubated for an hour at a 
concentration of 10 µg/mL with Hela cells over-expressing transferrin receptors [121]. To further 
verify the findings, ND-transferrin complexes were also added to Hela cells in which their 
transferrin receptors were presaturated by adding an excess of transferrin [121]. Upon excitation 
of the treated Hela cell samples using a 514.5 nm laser source, confocal fluorescence images 
were obtained by collecting fluorescence from 663 to 738 nm, thereby excluding most of the 
cellular autofluorescence background and providing high contrast images of NDs in cells (Figure 
2.9) [121]. While the successful internalization of transferrin was observed in Hela cells over- 
expressing transferrin receptors, no noticeable uptake occurred in transferrin receptor 
presaturated Hela cells as evidenced by the absence of ND fluorescence emission in the latter 
[121]. Hence, by using the fluorescence of NDs as a marker, it was confirmed that uptake of 
transferrin in Hela cells occurs through receptor mediated endocytosis [121].  Moreover, 100 nm 
size NDs did not interfere in the binding of transferrin to its receptor and subsequent cellular 
uptake [121].  As well, it was verified that the fluorescence of NDs originates from the lattice 
color defect center rather than surface defects, as the surface conjugation of NDs with transferrin, 
and transferrin-ND—transferrin receptor interactions had no adverse effects on their 
fluorescence properties [121].  Hence this result shows that NDs can act as an efficient label to 
examine the cellular uptake mechanism of various biomolecules.   
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Figure 2.9: Use of long wavelength emission of nanodiamonds in obtaining high contrast 
cellular images.  
 
Images of single Hela cell treated with ND-transferrin complex: (a) bright-field image, (b) 
confocal scanning image obtained by collecting all the fluorescence emission above 550 nm and 
(c) confocal scanning image obtained by collecting the fluorescence emission only from 663–738 
nm. 514.5 nm laser was used as excitation source. “Reprinted from [121] Copyright (2008), with 
permission from Elsevier.”   
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In addition to exploring the red fluorescence of type Ib irradiated/annealed synthetic NDs 
as cellular biomarker by various researchers [25,110,121], Mkandawire et al in 2009, proposed 
the use of untreated detonation NDs, emitting green fluorescence, for labeling live cells [135]. 
Immunoconjugated ND complexes were prepared by covalently coupling actin and 
mitochondrial targeted antibodies to the surface of oxidized NDs [135]. The actin antibody-ND 
and mitochondria antibody-ND immunoconjugates were then allowed internalization by Hela 
cells using maltotriose shelled 4
th
 generation dendrimers [135]. Using the green fluorescence of 
the NDs as a marker, live-cell fluorescence microscopic images of the treated cells, collected at 
535/40 nm wavelength, revealed selective targeting of actin and mitochondria by actin antibody-
ND and mitochondria antibody-ND immunoconjugates, respectively [135]. Moreover, with the 
rational selection of an antibody, NDs could also be designed to image the specific structures of 
the cells [135]. 
Further to the in vitro studies, Mohan et al in 2010, traced the movement of bare and 
bioconjugated red fluorescent NDs in Caenorhabditis elegans (Figure 2.10), a hermaphrodite 
having an optically transparent body [136]. The worms were deprived of Escherichia coli (E. 
coli), and then fed bare and dextran-/bovine serum albumin-conjugated carboxylated NDs [136]. 
The location of NDs in the worms was determined by differential interference and wide-field 
epifluorescence microscopic images, obtained by collecting the emission from the sample above 
600 nm wavelength upon excitation with green yellow light (510-560 nm) [136]. The bare NDs 
were found to be localized in the lumen of the worm 12 hours past administration with no signs 
of intestinal absorption [136]. However, the excretion of these NDs took place within an hour 
when the worms were fed on E. coli [136]. In contrast to the bare NDs, a major fraction of the 
bioconjugated NDs was taken up by the intestinal cells of the worm and remained there for 24 
hours despite E. coli feeding [136]. The high intestinal absorption of bioconjugated NDs 
compared to bare NDs was believed to be due to enhanced dispersibility of the NDs as a result of 
surface functionalization and/or triggering of certain cellular uptake pathways [136].  
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Figure 2.10: Internalization behavior of bare and surface functionalized nanodiamonds in 
Caenorhabditis elegans. 
 
(I) Images of Caenorhabditis elegans: (A) an untreated worm with labeled organ morphology; 
worms after oral administration of bare NDs for (B) 2 hours and (C) 12 hours; worms fed with 
bare NDs for 2 hours with subsequent administration of E. coli for (D) 20 minutes (E) and 40 
minutes. (B-E), Top, epifluorescence images; Bottom, epifluorescence and differential 
interference merged contrast images. (II) epifluorescence and differential interference contrast 
merged images of Caenorhabditis elegans: worms after 3 hours oral administration of (A) 
dextran conjugated NDs (B) bovine serum albumin conjugated NDs; worms fed Escherichia coli 
for 1 hour after treatment with (C) dextran-conjugated NDs and (D) bovine serum albumin-
conjugated NDs for 3 hours . Blue arrows indicate internalization of NDs in intestinal cells, 
yellow arrow indicate localization of NDs in lumen of worm. “Reprinted with permission from 
[136]. Copyright (2010) American Chemical Society.”   
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No photobleaching or photoblinking of NDs was observed even after 48 hours of 
continuous excitation with light [136]. Furthermore, observation of the lifespan, brood size, 
reactive oxygen species as well as stress response level demonstrated high biocompatibility of 
the NDs [136]. This study shows the potential for the use of the fluorescent properties of NDs in 
long term tracking of biomolecules in organisms, and as tools for marking human organelles 
[136].  
To date, there are a number of publications showing the utilization of ND fluorescence 
for imaging, mostly in the cells and less commonly in translucent organisms. However, further 
studies need to be carried out to demonstrate the usefulness of NDs as imaging agents in animals 
and humans. Imaging organisms that do not possess translucent membranes could pose a 
challenge. 
2.4.2 Elastic and Inelastic Light Scattering Imaging                                   
In addition to the fluorescence, NDs have a refractive index of 2.42,  thus possess 
characteristic optical scattering properties [119]. This property was explored by Smith et al by 
obtaining differential interference contrast microscopic images of 55 nm sized NDs internalized 
into 3T3 mammalian epithelial cells [137]. Based upon the differences in refractive indices of 
cellular structures and diamond, the diamond nanocrystal causes 300 times higher Rayleigh light 
scattering than the cellular structures of comparable sizes [138]. This offers an advantage to 
using NDs for obtaining high contrast imaging in the cells. In addition to elastic scattering [137], 
NDs are also capable of scattering light inelastically and hence are Raman-active [139,140]. The 
phonon mode of the diamond carbon shows a sharp and distinguished Raman signal at 1332 cm
-1 
[141] providing an opportunity for spectroscopic characterization and mapping of NDs in the 
cells. Raman spectroscopy is a non-invasive, non-toxic technique, therefore possesses potential 
to be used for detection and imaging of NDs in biological samples. Also, Raman spectroscopic 
measurements do not require complicated sample preparation and conditions that are hard to 
maintain, such as vacuum. Therefore, in addition to the fluorescent tag, NDs can also be used as 
an optical scattering nanoprobe in cellular studies. 
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In 2007, Perevedentseva et al used NDs as nanobioprobes to observe biomolecule-
bacterial interactions in vivo, using the unique Raman signal of NDs as a detection marker [139]. 
Physical adsorption of lysozymes was performed on carboxylated NDs and the resultant 
carboxylated ND-lysozyme complex was then allowed to interact with E. coli [139]. The optical 
microscope located the E. coli, while the confocal Raman spectrometer mapped the Raman 
signals from the NDs [139]. As the lysozyme was adsorbed onto the surface of the NDs, the 
overlay of optical and Raman images, revealed the interaction sites of the lysozyme with E. coli 
(Figure 2.11) [139]. This dual imaging provided a simple method to observe the interaction of 
molecules with living cells [139]. Furthermore, there was no reduction in the bactericidal activity 
of lysozymes upon adsorption onto the NDs surface, proving that  NDs did not interfere with the 
therapeutic activity of the attached entity [139]. 
The same group in 2007 investigated the use of NDs to predict the location of growth 
hormone receptors in human lung cancer cells by identifying the sp
3 
carbon Raman signals of 
NDs [140]. Growth hormone-ND complexes were created by carboxylating and covalently 
linking 100 nm sized NDs to the growth hormone [140]. When mapped by confocal Raman 
spectrophotometry, the NDs bound to growth hormone were located on the surface of a cell, 
while the unconjugated carboxylated NDs were internalized into the cells [140]. These 
observations verified the extracellular location of the growth hormone receptor using the Raman 
signal of the ND as a label [140]. This study provided a relatively easy and direct method of 
locating receptors at the cellular level. This method could be beneficial in investigating the 
receptor-mediated internalization of biomolecules and diagnosing diseases such as cancers 
involving the alteration in expression of certain receptors [140].  
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Figure 2.11: Use of nanodiamonds for predicting interaction between lysozymes and 
Escherichia coli. 
 
Lysozymal interaction sites revealed with E. coli: I.carboxylated NDs and E. coli, II. 
carboxylated NDs-lysoszyme complex and E. coli. (a) Optical images identifying E. coli; (b) 
confocal Raman mapping identifying nanodiamonds present in the square area outlined in optical 
image; (c) merging of the optical image with Raman mapping demonstrating the interaction of 
lysozyme with E. coli [139].“Reproduced courtesy of IOP Publishing Ltd". 
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 Conclusions 2.5
Continued investigation and understanding of disaggregation methods, surface properties, 
functionalization, biocompatibility, cellular fate, fluorescence as well as optical scattering 
characteristics of NDs have opened new horizons for their applications in the biomedical field. 
NDs have shown great potential to emerge as a platform for delivering drugs into biological 
systems due to their biocompatibility, high loading capacity and ability to cross cellular 
membranes. These particles have imparted sustained release and hydrophilic characteristics to 
water insoluble drugs, and have opened the possibilities for systemic administration of highly 
effective, hydrophobic chemotherapeutic molecules. While (N-V) defect centers are responsible 
for conferring fluorescence to NDs, the scattering properties originates from their high refractive 
index and Raman optical activity. These properties provide imaging capabilities to NDs for their 
detection in the cell. The multifunctional characteristics of NDs can be utilized to improve the 
delivery of drugs in conjunction with imaging their fate in biological systems, which can 
revolutionize studies in the area of life sciences. This unique biomaterial could be further 
explored as a gene delivery vehicle and a label to identify the biomolecular targets of drugs. 
 
  
  
 
   56 
  
 
 References 2.6
1. Shenderova OA, Mc.Guire G: Types of nanocrystalline diamond. In Ultrananocrystalline 
Diamond: Synthesis, Properties, and Applications. Edited by Shenderova OA, Gruen 
DM: William Andrew Publishing; 2006:79-114.  
2. Mochalin VN, Shenderova O, Ho D, Gogotsi Y: The properties and applications of 
nanodiamonds. Nature Nanotechnology 2012, 7:11-23. 
3. Gracio JJ, Fan QH, Madaleno JC: Diamond growth by chemical vapour deposition. Journal of 
Physics D: Applied Physics 2010, 43. 
4. Philip J, Hess P, Feygelson T, Butler JE, Chattopadhyay S, Chen KH, Chen LC: Elastic, 
mechanical, and thermal properties of nanocrystalline diamond films. Journal of Applied 
Physics 2003, 93:2164-2171. DOI: http://dx.doi.org/10.1063/1.1537465. 
5. Zhou D, Gruen DM, Qin LC, McCauley TG, Krauss AR: Control of diamond film 
microstructure by Ar additions to CH4/H2 microwave plasmas. Journal of Applied 
Physics 1998, 84:1981-1989. 
6. Qin LC, Zhou D, Krauss AR, Gruen DM: TEM characterization of nanodiamond thin films. 
Nanostructured Materials 1998, 10:649-660. 
7. Espinosa HD, Peng B, Prorok BC, Moldovan N, Auciello O, Carlisle JA, Gruen DM, Mancini 
DC: Fracture strength of ultrananocrystalline diamond thin films - Identification of 
Weibull parameters. Journal of Applied Physics 2003, 94:6076-6084. 
8. Angadi MA, Watanabe T, Bodapati A, Xiao X, Auciello O, Carlisle JA, Eastman JA, 
Keblinski P, Schelling PK, Phillpot SR: Thermal transport and grain boundary 
conductance in ultrananocrystalline diamond thin films. Journal of Applied Physics 2006, 
99:114301. 
9. Butler JE, Sumant AV: The CVD of nanodiamond materials. Chemical Vapor Deposition 
2008, 14:145-160. 
10. Sumant AV, Grierson DS, Gerbi JE, Carlisle JA, Auciello O, Carpick RW: Surface chemistry 
and bonding configuration of ultrananocrystalline diamond surfaces and their effects on 
nanotribological properties. Physical Review B - Condensed Matter and Materials 
Physics 2007, 76:235429. Link: http://link.aps.org/doi/10.1103/PhysRevB.76.235429. 
11. Bajaj P, Akin D, Gupta A, Sherman D, Shi B, Auciello O, Bashir R: Ultrananocrystalline 
diamond film as an optimal cell interface for biomedical applications. Biomedical 
Microdevices 2007, 9:787-794. 
  
 
   57 
  
 
12. Shi B, Jin Q, Chen L, Auciello O: Fundamentals of ultrananocrystalline diamond (UNCD) 
thin films as biomaterials for developmental biology: Embryonic fibroblasts growth on 
the surface of (UNCD) films. Diamond and Related Materials 2009, 18:596-600. 
13. Krauss AR, Auciello O, Gruen DM, Jayatissa A, Sumant A, TucekJ, Mancini DC, Moldovan 
N, Erdemir A, Ersoy D, et al.: Ultrananocrystalline diamond thin films for MEMS and 
moving mechanical assembly devices. Diamond and Related Materials 2001, 10:1952-
1961. 
14. Auciello O, Birrell J, Carlisle JA, Gerbi JE, Xiao X, Peng B, Espinosa HD: Materials science 
and fabrication processes for a new MEMS technology based on ultrananocrystalline 
diamond thin films. Journal of Physics Condensed Matter 2004, 16:R539-R552. 
15. Auciello O, Sumant AV: Status review of the science and technology of ultrananocrystalline 
diamond (UNCD™) films and application to multifunctional devices. Diamond and 
Related Materials 2010, 19:699-718. 
16. Sumant AV, Auciello O, Carpick RW, Srinivasan S, Butler JE: Ultrananocrystalline and 
nanocrystalline diamond thin films for MEMS/NEMS applications. MRS Bulletin 2010, 
35:281-288. 
17. Hupert M, Muck A, Wang J, Stotter J, Cvackova Z, Haymond S, Show Y, Swain GM: 
Conductive diamond thin-films in electrochemistry. Diamond and Related Materials 
2003, 12:1940-1949. 
18. Yang W, Auciello O, Butler JE, Cai W, Carlisle JA, Gerbi J, Gruen DM, Knickerbocker T, 
Lasseter TL, Russell Jr JN, et al.: DNA-modified nanocrystalline diamond thin-films as 
stable, biologically active substrates. Nature Materials 2002, 1:253-257. 
19. Chang YR, Lee HY, Chen K, Chang CC, Tsai DS, Fu CC, Lim TS, Tzeng YK, Fang CY, 
Han CC, et al.: Mass production and dynamic imaging of fluorescent nanodiamonds. 
Nature Nanotechnology 2008, 3:284-288. 
20. Sonnefraud Y, Cuche A, Faklaris O, Boudou JP, Sauvage T, Roch JF, Treussart F, Huant S: 
Diamond nanocrystals hosting single nitrogen-vacancy color centers sorted by photon-
correlation near-field microscopy. Optics Letters 2008, 33:611-613. 
21. Boudou JP, Curmi PA, Jelezko F, Wrachtrup J, Aubert P, Sennour M, Balasubramanian G, 
Reuter R, Thorel A, Gaffet E: High yield fabrication of fluorescent nanodiamonds. 
Nanotechnology 2009, 20:235602. 
22. Chang HC: Development and Use of Fluorescent Nanodiamonds as Cellular Marker. In 
Nanodiamonds: Applications in Biology and Nanoscale Medicine. Edited by Ho D: 
Springer; 2009:127-150.  
  
 
   58 
  
 
23. Davies G, Lawson SC, Collins AT, Mainwood A, Sharp SJ: Vacancy-related centers in 
diamond. Physical Review B 1992, 46:13157-13170. 
24. Clark CD, Norris CA: Photoluminescence associated with the 1.673, 1.944 and 2.498 eV 
centres in diamond. Journal of Physics C: Solid State Physics 1971, 4:2223-2229. 
25. Fu CC, Lee HY, Chen K, Lim TS, Wu HY, Lin PK, Wei PK, Tsao PH, Chang HC, Fann W: 
Characterization and application of single fluorescent nanodiamonds as cellular 
biomarkers. Proceedings of the National Academy of Sciences of the United States of 
America 2007, 104:727-732. DOI: 10.1073/pnas.0605409104 
26. Dolmatov VY: Detonation synthesis ultradispersed diamonds: Properties and applications. 
Russian Chemical Reviews 2001, 70:607-626. 
27. Dolmatov VY: Synthesis and post-synthesis treatment of detonation nanodiamonds. In 
Ultrananocrystalline Diamond: Synthesis, Properties, and Applications. Edited by 
Shenderova OA, Gruen DM: William Andrew Publishing; 2006:347-377.  
28. Shenderova OA, Zhirnov VV, Brenner DW: Carbon nanostructures. Critical Reviews in Solid 
State and Materials Sciences 2002, 27:227-356. 
29. Baidakova M, Vul A: New prospects and frontiers of nanodiamond clusters. Journal of 
Physics D: Applied Physics 2007, 40:6300-6311. DOI: 10.1088/0022-3727/40/20/S14 
30. Aleksenskii AE, Baidakova MV, Vul AY, Siklitskii VI: The structure of diamond 
nanoclusters. Physics of the Solid State 1999, 41:668-671. 
31. Shenderova OA, Hens SAC: Detonation nanodiamond particles processing, modification and 
bioapplications. In Nanodiamonds: Applications in Biology and Nanoscale Medicine. 
Edited by Ho D: Springer; 2010:79-116.  
32. Pichot V, Comet M, Fousson E, Baras C, Senger A, Le Normand F, Spitzer D: An efficient 
purification method for detonation nanodiamonds. Diamond and Related Materials 2008, 
17:13-22. 
33. Osswald S, Yushin G, Mochalin V, Kucheyev SO, Gogotsi Y: Control of sp2/sp3 carbon 
ratio and surface chemistry of nanodiamond powders by selective oxidation in air. 
Journal of the American Chemical Society 2006, 128:11635-11642. 
34. Petrov I, Shenderova O, Grishko V, Grichko V, Tyler T, Cunningham G, McGuire G: 
Detonation nanodiamonds simultaneously purified and modified by gas treatment. 
Diamond and Related Materials 2007, 16:2098-2103. 
35. Krüger A, Kataoka F, Ozawa M, Fujino T, Suzuki Y, Aleksenskii AE, Vul AY, Osawa E: 
Unusually tight aggregation in detonation nanodiamond: Identification and disintegration. 
Carbon 2005, 43:1722-1730. 
  
 
   59 
  
 
36. Krueger A: The structure and reactivity of nanoscale diamond. Journal of Materials 
Chemistry 2008, 18:1485-1492. 
37. Jiang T, Xu K: FTIR study of ultradispersed diamond powder synthesized by explosive 
detonation. Carbon 1995, 33:1663-1671. 
38. Dolmatov VY: Detonation nanodiamonds in oils and lubricants. Journal of Superhard 
Materials 2010, 32:14-20. 
39. Schrand AM, Hens SAC, Shenderova OA: Nanodiamond Particles: Properties and 
Perspectives for Bioapplications. Critical Reviews in Solid State and Materials Sciences 
2009, 34:18-74. 
40. Bondar VS, Pozdnyakova IO, Puzyr AP: Applications of nanodiamonds for separation and 
purification of proteins. Physics of the Solid State 2004, 46:758-760. 
41. Purtov KV, Puzyr AP, Bondar VS: Nanodiamond sorbents: New carriers for column 
chromatography of proteins. Doklady Biochemistry and Biophysics 2008, 419:72-74. 
42. Dolmatov VY: Applications of detonation nanodiamond. In Ultrananocrystalline Diamond: 
Synthesis, Properties, and Applications. Edited by Shenderova OA, Gruen DM: William 
Andrew Publishing; 2006:477-527.  
43. Pentecost A, Gour S, Mochalin V, Knoke I, Gogotsi Y: Deaggregation of nanodiamond 
powders using salt- and sugar-assisted milling. ACS Applied Materials and Interfaces 
2010, 2:3289-3294. 
44. Krüger A, Liang Y, Jarre G, Stegk J: Surface functionalisation of detonation diamond 
suitable for biological applications. Journal of Materials Chemistry 2006, 16:2322-2328. 
45. Barnard AS: Self-assembly in nanodiamond agglutinates. Journal of Materials Chemistry 
2008, 18:4038-4041. 
46. Chang LY, Sawa E, Barnard AS: Confirmation of the electrostatic self-assembly of 
nanodiamonds. Nanoscale 2011, 3:958-962. 
47. Ozawa M, Inaguma M, Takahashi M, Kataoka F, Krüger A, Osawa E: Preparation and 
behavior of brownish, clear nanodiamond colloids. Advanced Materials 2007, 19:1201-
1206. 
48. Liang Y, Ozawa M, Krueger A: A general procedure to functionalize agglomerating 
nanoparticles demonstrated on nanodiamond. ACS Nano 2009, 3:2288-2296. 
49. Osawa E: Recent progress and perspectives in single-digit nanodiamond. Diamond and 
Related Materials 2007, 16:2018-2022. 
  
 
   60 
  
 
50. Eidelman ED, Siklitsky VI, Sharonova LV, Yagovkina MA, Vul AY, Takahashi M, Inakuma 
M, Ozawa M, Osawa E: A stable suspension of single ultrananocrystalline diamond 
particles. Diamond and Related Materials 2005, 14:1765-1769. 
51. Suslick KS, Hammerton DA, Cline  RE: The sonochemical hot spot. Journal of the American 
Chemical Society 1986, 108:5641-5642. 
52. Aleksenskii AE, Baidakova MV, Vul AY, Davydov VY, Pevtsova YA: Diamond-graphite 
phase transition in ultradisperse-diamond clusters. Physics of the Solid State 1997, 
39:1007-1015. 
53. Xu X, Yu Z, Zhu Y, Wang B: Effect of sodium oleate adsorption on the colloidal stability 
and zeta potential of detonation synthesized diamond particles in aqueous solutions. 
Diamond and Related Materials 2005, 14:206-212. 
54. Morita Y, Takimoto T, Yamanaka H, Kumekawa K, Marino S, Aonuma S, Kimura T, 
Komatsu N: A facile and scalable process for size-controllable separation of 
nanodiamond particles as small as 4 nm. Small 2008, 4:2154-2157. 
55. Tsubota T, Tanii S, Ida S, Nagata M, Matsumoto Y: Chemical modification of diamond 
surface with various carboxylic acids by radical reaction in liquid phase. Diamond and 
Related Materials 2004, 13:1093-1097. 
56. Ida S, Tsubota T, Tanii S, Nagata M, Matsumoto Y: Chemical modification of the diamond 
surface using benzoyl peroxide and dicarboxylic acids. Langmuir 2003, 19:9693-9698. 
57. Ando T, Nishitani-Gamo M, Rawles RE, Yamamoto K, Kamo M, Sato Y: Chemical 
modification of diamond surfaces using a chlorinated surface as an intermediate state. 
Diamond and Related Materials 1996, 5:1136-1142. 
58. Liu Y, Gu Z, Margrave JL, Khabashesku VN: Functionalization of nanoscale diamond 
powder: Fluoro-, alkyl-, amino-, and amino acid-nanodiamond derivatives. Chemistry of 
Materials 2004, 16:3924-3930. 
59. Krueger A, Boedeker T: Deagglomeration and functionalisation of detonation nanodiamond 
with long alkyl chains. Diamond and Related Materials 2008, 17:1367-1370. 
60. Krueger A, Ozawa M, Jarre G, Liang Y, Stegk J, Lu L: Deagglomeration and 
functionalisation of detonation diamond. Physica Status Solidi (A) Applications and 
Materials 2007, 204:2881-2887. 
61. Krueger A, Stegk J, Liang Y, Lu L, Jarre G: Biotinylated nanodiamond: Simple and efficient 
functionalization of detonation diamond. Langmuir 2008, 24:4200-4204. 
62. Schrand AM, Huang H, Carlson C, Schlager JJ, Osawa E, Hussain SM, Dai L: Are diamond 
nanoparticles cytotoxic? Journal of Physical Chemistry B 2007, 111:2-7. 
  
 
   61 
  
 
63. Schrand AM, Dai L, Schlager JJ, Hussain SM, Osawa E: Differential biocompatibility of 
carbon nanotubes and nanodiamonds. Diamond and Related Materials 2007, 16:2118-
2123. 
64. Yu SJ, Kang MW, Chang HC, Chen KM, Yu YC: Bright fluorescent nanodiamonds: No 
photobleaching and low cytotoxicity. Journal of the American Chemical Society 2005, 
127:17604-17605. 
65. Liu KK, Cheng CL, Chang CC, Chao JI: Biocompatible and detectable carboxylated 
nanodiamond on human cell. Nanotechnology 2007, 18:325102. 
66. Chao JI, Perevedentseva E, Chung PH, Liu KK, Cheng CY, Chang CC, Cheng CL: 
Nanometer-sized diamond particle as a probe for biolabeling. Biophysical Journal 2007, 
93:2199-2208. 
67. Huang H, Pierstorff E, Osawa E, Ho D: Active nanodiamond hydrogels for chemotherapeutic 
delivery. Nano Letters 2007, 7:3305-3314. 
68. Li J, Zhu Y, Li W, Zhang X, Peng Y, Huang Q: Nanodiamonds as intracellular transporters 
of chemotherapeutic drug. Biomaterials 2010, 31:8410-8418. 
69. Xing Y, Xiong W, Zhu L, Osawa E, Hussin S, Dai L: DNA damage in embryonic stem cells 
caused by nanodiamonds. ACS Nano 2011, 5:2376-2384. 
70. Marcon L, Riquet F, Vicogne D, Szunerits S, Bodart JF, Boukherroub R: Cellular and in vivo 
toxicity of functionalized nanodiamond in Xenopus embryos. Journal of Materials 
Chemistry 2010, 20:8064-8069. 
71. Liu K-K, Wang C-C, Cheng C-L, Chao J-I: Endocytic carboxylated nanodiamond for the 
labeling and tracking of cell division and differentiation in cancer and stem cells. 
Biomaterials 2009, 30:4249-4259. 
72. Zhu L, Chang DW, Dai L, Hong Y: DNA damage induced by multiwalled carbon nanotubes 
in mouse embryonic stem cells. Nano Letters 2007, 7:3592-3597. 
73. Zhu Y, Li W, Li Q, Li Y, Zhang X, Huang Q: Effects of serum proteins on intracellular 
uptake and cytotoxicity of carbon nanoparticles. Carbon 2009, 47:1351-1358. 
74. Drescher D, Orts-Gil G, Laube G, Natte K, Veh RW, Österle W, Kneipp J: Toxicity of 
amorphous silica nanoparticles on eukaryotic cell model is determined by particle 
agglomeration and serum protein adsorption effects. Analytical and Bioanalytical 
Chemistry 2011, 400:1367-1373. 
75. Kittler S, Greulich C, Gebauer JS, Diendorf J, Treuel L, Ruiz L, Gonzalez-Calbet JM, Vallet-
Regi M, Zellner R, Köller M, et al.: The influence of proteins on the dispersability and 
  
 
   62 
  
 
cell-biological activity of silver nanoparticles. Journal of Materials Chemistry 2010, 
20:512-518. 
76. Casey A, Davoren M, Herzog E, Lyng FM, Byrne HJ, Chambers G: Probing the interaction 
of single walled carbon nanotubes within cell culture medium as a precursor to toxicity 
testing. Carbon 2007, 45:34-40. 
77. Guo L, Von Dem Bussche A, Buechner M, Yan A, Kane AB, Hurt RH: Adsorption of 
essential micronutrients by carbon nanotubes and the implications for nanotoxicity 
testing. Small 2008, 4:721-727. 
78. Puzyr AP, Baron AV, Purtov KV, Bortnikov EV, Skobelev NN, Mogilnaya OA, Bondar VS: 
Nanodiamonds with novel properties: A biological study. Diamond and Related 
Materials 2007, 16:2124-2128. 
79. Yuan Y, Wang X, Jia G, Liu JH, Wang T, Gu Y, Yang ST, Zhen S, Wang H, Liu Y: 
Pulmonary toxicity and translocation of nanodiamonds in mice. Diamond and Related 
Materials 2010, 19:291-299. 
80. Chow EK, Zhang XQ, Chen M, Lam R, Robinson E, Huang H, Schaffer D, Osawa E, Goga 
A, Ho D: Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant 
tumor treatment. Science Translational Medicine 2011, 3:73ra21. 
81. Faklaris O, Garrot D, Joshi W, Druon F, Boudou JP, Sauvage T, Georges P, Curmi PA, 
Treussart F: Detection of single photoluminescent diamond nanoparticles in cells and 
study of the internalization pathway. Small 2008, 4:2236-2239. 
82. Wee TL, Mau YW, Fang CY, Hsu HL, Han CC, Chang HC: Preparation and characterization 
of green fluorescent nanodiamonds for biological applications. Diamond and Related 
Materials 2009, 18:567-573. 
83. Faklaris O, Joshi V, Irinopoulou T, Tauc P, Sennour M, Girard H, Gesset C, Arnault JC, 
Thorel A, Boudou JP, et al.: Photoluminescent diamond nanoparticles for cell labeling: 
Study of the uptake mechanism in mammalian cells. ACS Nano 2009, 3:3955-3962. 
84. Martín R, Álvaro M, Herance JR, García H: Fenton-treated functionalized diamond 
nanoparticles as gene delivery system. ACS Nano 2010, 4:65-74. 
85. Li X, Shao J, Qin Y, Shao C, Zheng T, Ye L: TAT-conjugated nanodiamond for the 
enhanced delivery of doxorubicin. Journal of Materials Chemistry 2011, 21:7966-7973. 
86. Liu KK, Zheng WW, Wang CC, Chiu YC, Cheng CL, Lo YS, Chen C, Chao JI: Covalent 
linkage of nanodiamond-paclitaxel for drug delivery and cancer therapy. Nanotechnology 
2010, 21:315106. 
  
 
   63 
  
 
87. Chen M, Pierstorff ED, Lam R, Li SY, Huang H, Osawa E, Ho D: Nanodiamond-mediated 
delivery of water-insoluble therapeutics. ACS Nano 2009, 3:2016-2022. 
88. Mohanraj VJ, Chen Y: Nanoparticles -A Review. Tropical Journal of Pharmaceutical 
Research 2006, 5:561-573. 
89. Sinha R, Kim GJ, Nie S, Shin DM: Nanotechnology in cancer therapeutics: Bioconjugated 
nanoparticles for drug delivery. Molecular Cancer Therapeutics 2006, 5:1909-1917. 
90. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM: Inhibition of CDK1 as a potential 
therapy for tumors over-expressing MYC. Nature Medicine 2007, 13:820-827. 
91. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS: Potential role of tamoxifen in 
prevention of breast cancer. Journal of the National Cancer Institute 1991, 83:1450-
1459. 
92. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers 
TB, Kavanah MT, Atkins JN, Margolese RG, et al.: Tamoxifen for the prevention of 
breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project 
P-1 study. Journal of the National Cancer Institute 2005, 97:1652-1662. 
93. Liang XJ, Chen C, Zhao Y, Wang PC: Circumventing tumor resistance to chemotherapy by 
nanotechnology. Methods in molecular biology (Clifton, N.J.) 2010, 596:467-488. 
94. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R: Nanocarriers as an 
emerging platform for cancer therapy. Nature Nanotechnology 2007, 2:751-760. 
95. Moorthi C, Manavalan R, Kathiresan K: Nanotherapeutics to overcome conventional cancer 
chemotherapy limitations. Journal of Pharmacy and Pharmaceutical Sciences 2011, 
14:67-77. 
96. Shimkunas RA, Robinson E, Lam R, Lu S, Xu X, Zhang XQ, Huang H, Osawa E, Ho D: 
Nanodiamond-insulin complexes as pH-dependent protein delivery vehicles. 
Biomaterials 2009, 30:5720-5728. 
97. Liu Y, Petreaca M, Yao M, Martins-Green M: Cell and molecular mechanisms of 
keratinocyte function stimulated by insulin during wound healing. BMC Cell Biology 
2009, 10:1. 
98. Schneider LA, Korber A, Grabbe S, Dissemond J: Influence of pH on wound-healing: A new 
perspective for wound-therapy? Archives of Dermatological Research 2007, 298:413-
420. 
99. Wiethoff CM, Middaugh CR: Barriers to nonviral gene delivery. Journal of Pharmaceutical 
Sciences 2003, 92:203-217. 
  
 
   64 
  
 
100. Gary DJ, Puri N, Won YY: Polymer-based siRNA delivery: Perspectives on the 
fundamental and phenomenological distinctions from polymer-based DNA delivery. 
Journal of Controlled Release 2007, 121:64-73. 
101. Whitehead KA, Langer R, Anderson DG: Knocking down barriers: Advances in siRNA 
delivery. Nature Reviews Drug Discovery 2009, 8:129-138. 
102. Takahashi Y, Nishikawa M, Takakura Y: Nonviral vector-mediated RNA interference: Its 
gene silencing characteristics and important factors to achieve RNAi-based gene therapy. 
Advanced Drug Delivery Reviews 2009, 61:760-766. 
103. Van De Water FM, Boerman OC, Wouterse AC, Peters JGP, Russel FGM, Masereeuw R: 
Intravenously administered short interfering RNA accumulates in the kidney and 
selectively suppresses gene function in renal proximal tubules. Drug Metabolism and 
Disposition 2006, 34:1393-1397. 
104. Zhang XQ, Chen M, Lam R, Xu X, Osawa E, Ho D: Polymer-functionalized nanodiamond 
platforms as vehicles for gene delivery. ACS Nano 2009, 3:2609-2616. 
105. Chen M, Zhang XQ, Man HB, Lam R, Chow EK, Ho D: Nanodiamond vectors 
functionalized with polyethylenimine for siRNA delivery. Journal of Physical Chemistry 
Letters 2010, 1:3167-3171. 
106. Ramdas AK: Electronic excitations in isotopically controlled diamonds:infrared and Raman 
spectroscopy of acceptor-bound holes. In Properties, Growth and applications of 
Diamond. Edited by Neves AJ, Nazaré MH: INSPEC; 2001:21-27.  
107. Kiflawi I, Lawson SC: Aggregates of nitrogen in diamond. In Properties, Growth and 
Applications of Diamond. Edited by Neves AJ, Nazaré, Helana M: INSPEC; 2001:130-
135.  
108. Vaijayanthimala V, Chang HC: Functionalized fluorescent nanodiamonds for biomedical 
applications. Nanomedicine 2009, 4:47-55. 
109. Mainwood A: Nitrogen and nitrogen-vacancy complexes and their formation in diamond. 
Physical Review B 1994, 49:7934-7940. 
110. Neugart F, Zappe A, Jelezko F, Tietz C, Boudou JP, Krueger A, Wrachtrup J: Dynamics of 
diamond nanoparticles in solution and cells. Nano Letters 2007, 7:3588-3591. 
111. Treussart F, Jacques V, Wu E, Gacoin T, Grangier P, Roch JF: Photoluminescence of single 
colour defects in 50 nm diamond nanocrystals. Physica B: Condensed Matter 2006, 376-
377:926-929. 
  
 
   65 
  
 
112. Davies G, Hamer MF: Optical Studies of the 1.945 eV Vibronic Band in Diamond. 
Proceedings of the Royal Society of London.A.Mathematical and Physical Sciences 1976, 
348:285-298. 
113. Wee TL, Tzeng YK, Han CC, Chang HC, Fann W, Hsu JH, Chen KM, Yu EC: Two-photon 
excited fluorescence of nitrogen-vacancy centers in proton-irradiated type Ib diamond. 
Journal of Physical Chemistry A 2007, 111:9379-9386. 
114. Lawson SC, Fisher D, Hunt DC, Newton ME: On the existence of positively charged 
single-substitutional nitrogen in diamond. Journal of Physics Condensed Matter 1998, 
10:6171-6180. 
115. Hui YY, Chang YR, Mohan N, Lim TS, Chen YY, Chang HC: Polarization modulation 
spectroscopy of single fluorescent nanodiamonds with multiple nitrogen vacancy centers. 
Journal of Physical Chemistry A 2011, 115:1878-1884. 
116. Gruber A, Dräbenstedt A, Tietz C, Fleury L, Wrachtrup J, Von Borczyskowski C: Scanning 
confocal optical microscopy and magnetic resonance on single defect centers. Science 
1997, 276:2012-2014. 
117. Collins AT, Thomaz MF, Jorge MIB: Luminescence decay time of the 1.945 eV centre in 
type Ib diamond. Journal of Physics C: Solid State Physics 1983, 16:2177-2181. 
118. Tisler J, Balasubramanian G, Naydenov B, Kolesov R, Grotz B, Reuter R, Boudou JP, 
Curmi PA, Sennour M, Thorel A, et al.: Fluorescence and spin properties of defects in 
single digit nanodiamonds. ACS Nano 2009, 3:1959-1965. 
119. Hui YY, Cheng CL, Chang HC: Nanodiamonds for optical bioimaging. Journal of Physics 
D: Applied Physics 2010, 43:374021. 
120. Gali A, Fyta M, Kaxiras E: Ab initio supercell calculations on nitrogen-vacancy center in 
diamond: Electronic structure and hyperfine tensors. Physical Review B - Condensed 
Matter and Materials Physics 2008, 77:155206. 
121. Weng MF, Chiang SY, Wang NS, Niu H: Fluorescent nanodiamonds for specifically 
targeted bioimaging: Application to the interaction of transferrin with transferrin 
receptor. Diamond and Related Materials 2009, 18:587-591. DOI: 
10.1016/j.diamond.2008.07.012 
122. Koenig K, Schneckenburger H: Laser-induced autofluorescence for medical diagnosis. 
Journal of Fluorescence 1994, 4:17-40. 
123. Aubin JE: Autofluorescence of viable cultured mammalian cells. Journal of Histochemistry 
and Cytochemistry 1979, 27:36-43. 
124. Lichtman JW, Conchello JA: Fluorescence microscopy. Nature Methods 2005, 2:910-919. 
  
 
   66 
  
 
125. Dahan M, Laurence T, Pinaud F, Chemla DS, Alivisatos AP, Sauer M, Weiss S: Time-gated 
biological imaging by use of colloidal quantum dots. Optics Letters 2001, 26:825-827. 
126. Davies G: The effect of nitrogen impurity on the annealing of radiation damage in diamond. 
Journal of Physics C: Solid State Physics 1972, 5:2534-2542. 
127. Vlasov II, Shenderova O, Turner S, Lebedev OI, Basov AA, Sildos I, Rähn M, Shiryaev 
AA, Van Tendeloo G: Nitrogen and luminescent nitrogen-vacancy defects in detonation 
nanodiamond. Small 2010, 6:687-694. 
128. Borjanovic V, Lawrence WG, Hens S, Jaksic M, Zamboni I, Edson C, Vlasov I, Shenderova 
O, McGuire GE: Effect of proton irradiation on photoluminescent properties of PDMS-
nanodiamond composites. Nanotechnology 2008, 19:455701. 
129. Kvit AV, Zhirnov VV, Tyler T, Hren JJ: Aging effect and nitrogen distribution in diamond 
nanoparticles. Composites Part B: Engineering 2004, 35:163-166. 
130. Vlasov II, Barnard AS, Ralchenko VG, Lebedev OI, Kanzyuba MV, Saveliev AV, Konov 
VI, Goovaerts E: Nanodiamond photoemitters based on strong narrow-band 
luminescence from silicon-vacancy defects. Advanced Materials 2009, 21:808-812. 
131. Barnard AS, Sternberg M: Can we predict the location of impurities in diamond 
nanoparticles? Diamond and Related Materials 2007, 16:2078-2082. 
132. Smith BR, Inglis DW, Sandnes B, Rabeau JR, Zvyagin AV, Gruber D, Noble CJ, Vogel R, 
Ösawa E, Plakhotnik T: Five-nanometer diamond with luminescent nitrogen-vacancy 
defect centers. Small 2009, 5:1649-1653. 
133. Bradac C, Gaebel T, Naidoo N, Sellars MJ, Twamley J, Brown LJ, Barnard AS, Plakhotnik 
T, Zvyagin AV, Rabeau JR: Observation and control of blinking nitrogen-vacancy 
centres in discrete nanodiamonds. Nature Nanotechnology 2010, 5:345-349. 
134. Turner S, Lebedev OI, Shenderova O, Vlasov II, Verbeeck J, Van Tendeloo G: 
Determination of size, morphology, and nitrogen impurity location in treated detonation 
nanodiamond by transmission electron microscopy. Advanced Functional Materials 
2009, 19:2116-2124. 
135. Mkandawire M, Pohl A, Gubarevich T, Lapina V, Appelhans D, Rödel G, Pompe W, 
Schreiber J, Opitz J: Selective targeting of green fluorescent nanodiamond conjugates to 
mitochondria in HeLa cells. Journal of Biophotonics 2009, 2:596-606. 
136. Mohan N, Chen CS, Hsieh HH, Wu YC, Chang HC: In vivo imaging and toxicity 
assessments of fluorescent nanodiamonds in caenorhabditis elegans. Nano Letters 2010, 
10:3692-3699. DOI: 10.1021/nl1021909 
  
 
   67 
  
 
137. Smith BR, Niebert M, Plakhotnik T, Zvyagin AV: Transfection and imaging of diamond 
nanocrystals as scattering optical labels. Journal of Luminescence 2007, 127:260-263. 
138. Colpin Y, Swan A, Zvyagin AV, Plakhotnik T: Imaging and sizing of diamond 
nanoparticles. Optics Letters 2006, 31:625-627. 
139. Perevedentseva E, Cheng CY, Chung PH, Tu JS, Hsieh YH, Cheng CL: The interaction of 
the protein lysozyme with bacteria E. coli observed using nanodiamond labelling. 
Nanotechnology 2007, 18:315102. DOI: 10.1088/0957-4484/18/31/315102. 
140. Cheng CY, Perevedentseva E, Tu JS, Chung PH, Cheng CL, Liu KK, Chao JI, Chen PH, 
Chang CC: Direct and in vitro observation of growth hormone receptor molecules in 
A549 human lung epithelial cells by nanodiamond labeling. Applied Physics Letters 
2007, 90:163903. 
141. Knight DS, White WB: Characterization of diamond films by Raman spectroscopy. Journal 
of Materials Research 1989, 4:385-393. 
 
  
  
 
   68 
  
 
 
                                                                                                                        Chapter 3
HYPOTHESIS, OBJECTIVES AND RESEARCH OVERVIEW 
 Hypothesis 3.1
Mechanochemical functionalization of detonation nanodiamonds with lysine will lead to their 
significant disaggregation. 
The resulting lysine-functionalized nanodiamond particles will bind genetic materials by forming 
nano-sized complexes to deliver them into mammalian cells. 
 Objectives 3.2
3.2.1 Objective 1 
 To carry out covalent functionalization of nanodiamonds with lysine, attached to a 3-
carbon length spacer (1,3 diaminopropane), to obtain positively charged disaggregated 
nanoparticles. 
3.2.2 Objective 2 
 To characterize and evaluate the degree of functionalization of nanodiamonds with 
lysine-spacer. 
3.2.3 Objective 3 
 To determine the physiochemical properties of lysine-functionalized nanodiamonds and 
evaluate their binding properties with genetic materials to form “diamoplexes”. 
3.2.4 Objective 4 
 To evaluate in vitro toxicity of pristine carboxylated and lysine-functionalized 
nanodiamonds, cellular interaction of lysine-functionalized nanodiamonds, and 
investigate the gene delivery efficacy of the selected “diamoplexes” in Hela cell line. 
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 Research Overview 3.3
Pristine carboxylated nanodiamonds (pNDs) when dispersed in an aqueous medium 
assemble to form micron-sized aggregates. Several attempts were made to disaggregate these 
NDs by using surfactants, bath sonication, probe sonication and sonication with grinding media 
(Appendix A). Moreover, the time-dependent effects of bath and probe sonication on the 
dispersion stability of NDs were also examined (Appendix A). None of these approaches were 
successful in achieving a considerable disaggregation; in some cases, there was no 
disaggregation observed, while in other instances, re-aggregation occurred immediately after 
removing the mechanical energy treatment. Therefore, my aim was to develop an approach that 
could lead to a considerable disaggregation of NDs such that the resulting disaggregated particles 
have the potential to act as carriers of nucleic acids. 
To serve the purposes of disaggregation and generation of positive charge on NDs, 
functionalization of NDs with lysine, accompanied with the mechanical disaggregation, was 
carried out. Firstly, these two techniques together were expected to bring disaggregation of ND 
aggregate diamond particles, based upon the rationale that the moment the mechanical treatment 
will disaggregate the diamond particles, the lysine functionalization on the NDs surfaces will 
generate inter-particle steric hindrances, thereby circumventing their re-aggregation. Secondly, 
the lysine molecule attached to NDs, due to its basicity, was expected to provide an overall 
positive charge to the surfaces of each lysine-functionalized NDs (fNDs) at neutral pH, thereby 
making them the suitable candidates for binding nucleic acids. Moreover, the like-positive 
charges on the surfaces of fNDs were expected to contribute towards post-functionalization 
disaggregation by generating inter-particle repulsive behavior.  
To verify the successful functionalization of NDs with lysine, Raman and Fourier 
Transform Infrared spectroscopy was performed. The Raman spectroscopy has the potential to 
identify the diamond carbon as well as the other functional groups that show a change in 
polarizability with the molecular vibrations, therefore was considered to be the most suitable 
technique to examine the functionalization of NDs with lysine. But the fluorescence induced 
swamping of Raman signals in fND spectra, required me to perform infrared spectroscopic 
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measurements as well, to verify the functionalization of NDs. Moreover, the Raman and infrared 
spectroscopy, due to their different selection rules, are complementary to each other and 
therefore generally used together for characterization purposes. Thermogravimetric analysis was 
performed to quantitate the surface loading on the ND surfaces.  
To determine if the current approach of mechanochemical functionalization was effective 
in inducing disaggregation of the ND aggregates, dynamic light scattering and atomic force 
microscopic measurements were carried out. Dynamic light scattering measures the 
hydrodynamic diameter of the material, hence useful in determining the actual size of the 
particles in their formulation medium; whereas the atomic force microscopy assist in 
visualization of particles, hence suitable to provide a visual evidence of disaggregation. In 
addition, the zeta potential of fNDs dispersion in water was measured to find out if the 
dispersions were stable enough to advocate their use for in vitro studies.  
To examine the binding behavior of the disaggregated fNDs with plasmid DNA (pDNA) 
and small interfering RNA (siRNA), gel-retardation assay, dynamic light scattering and zeta 
potential measurements were performed. The gel-retardation assay was expected not to show the 
migration of the nucleic acids towards anode if fNDs were binding nucleic acid effectively. The 
purpose of using pDNA and siRNA was to probe the differences in binding patterns of two, 
structurally different genetic materials with the same solid-core positively charged nanoparticles, 
if any. Furthermore, it is crucial to determine the size of carrier-nucleic acid complex as the 
particles with the size less than 300 nm are required for the efficient cellular internalization. 
Other than the size, the surface of carrier-nucleic acid complex should have positive charge for 
effective interaction with cell surface that would favor their cellular uptake. Moreover, the 
overall positive zeta potential of the fNDs-nucleic acid complex would also indicate the absence 
of any unbound nucleic acids. 
To test the biocompatibility of NDs, MTT cytotoxicity assay performed. As majority of 
the transfection studies are performed in cell culture medium lacking serum, therefore it was 
important to determine if the lack of serum have a substantial effect on cellular viability. 
Therefore, both the treatment conditions, with serum and without serum, were tested. To further 
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substantiate its potential as an efficient delivery agent, the material itself should demonstrate 
cellular interaction and ultimately internalization, which in this study was examined by using 
Raman-fluorescence, backscattering and laser scanning confocal microscopy. The rationale of 
using Raman-fluorescence mapping was based upon the observed fluorescence of the NDs in 
Raman spectral measurements, thus were expected to generate a higher Raman intensity regions 
in the NDs treated cells compared to the untreated cells or the cellular regions devoid of NDs. 
Although the Raman-fluorescence mapping demonstrated the high intensity regions with NDs 
treated cells, but neither the diamond peak was successfully identified nor were the distinct areas, 
requiring me to use another technique to test the cellular association of NDs. As the diamond has 
a higher refractive index and density than the cell, therefore ND particles were expected to 
produce elastic scattering of the incident light at a relatively higher intensity, which could 
indicate their presence in the cells. The backscattering mapping provided a clear evidence of 
interaction of fNDs with cells, however as the imaging was conducted only in two dimensional 
frameworks, the cellular internalization cannot be proved from these. Three dimensional 
confocal microscopy was performed on fNDs treated cells based upon the rationale of detection 
of NDs in the cells using their intrinsic fluorescence.  
Finally, to determine the efficacy of fNDs to deliver anti GFP-siRNA in GFP expressing 
cells, fluorescence activated cell sorting was performed. The siRNA bound to the fNDs were 
expected to knockdown the GFP considerably, decreasing the overall GFP fluorescence intensity 
in the fNDs-siRNA treated cell population in comparison to the naked siRNA treated cells. 
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                                                                                                                       Chapter 4
LYSINE-FUNCTIONALIZED NANODIAMONDS: SYNTHESIS, PHYSIOCHEMICAL 
CHARACTERIZATION AND NUCELIC ACID BINDING STUDIES 
Kaur R, Chitanda JM, Michel D, Maley J, Borondics F, Yang P, Verrall RE, Badea I. 
International Journal of Nanomedicine.2012;1(7):3851-3866. 
Abstract 
Purpose: Detonation nanodiamonds (NDs) are carbon-based nanomaterials that, because of their 
size (4–5 nm), stable inert core, alterable surface chemistry, fluorescence, and biocompatibility, 
are emerging as bioimaging agents and promising tools for the delivery of biochemical 
molecules into cellular systems. However, diamond particles possess a strong propensity to 
aggregate in liquid formulation media, restricting their applicability in biomedical sciences. 
Here, the authors describe the covalent functionalization of NDs with lysine in an attempt to 
develop nanoparticles able to act as suitable non-viral vectors for transferring genetic materials 
across cellular membranes. 
Methods: NDs were oxidized and functionalized by binding lysine moieties attached to a three-
carbon-length linker (1,3-diaminopropane) to their surfaces through amide bonds. Raman and 
Fourier transform infrared spectroscopy, zeta potential measurement, dynamic light scattering, 
atomic force microscopic imaging, and thermogravimetric analysis were used to characterize the 
lysine-functionalized NDs. Finally, the ability of the functionalized diamonds to bind plasmid 
DNA and small interfering RNA was investigated by gel electrophoresis assay and through size 
and zeta potential measurements. 
Results: NDs were successfully functionalized with the lysine linker, producing surface loading 
of 1.7 mmol g
−1
 of ND. These modified NDs formed highly stable aqueous dispersions with a 
zeta potential of 49 mV and particle size of approximately 20 nm. The functionalized NDs were 
found to be able to bind plasmid DNA and small interfering RNA by forming nano-sized 
“diamoplexes”. 
Conclusion: The lysine-substituted ND particles generated in this study exhibit stable aqueous 
formulation and show potential for use as carriers for genetic materials. 
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 Introduction  4.1
In recent years, the scientific community has become increasingly interested in detonation 
nanodiamonds (NDs) because of their unique structural, chemical, optical, and biological 
characteristics [1]. NDs were first produced in Russia in the 1960s through the incomplete 
combustion of carbon-containing explosives [2]. While these diamond nanoparticles initially 
attracted the attention of the industrial world and have been utilized to improve the physical 
properties of polymers, the shelf life of mechanical tools, and in the electrochemical coating of 
metals [3], investigations into their nano-scale properties have recently placed significance on 
their biological applications [4-6]. 
The most attractive feature of NDs is their uniform nano-scale size distribution. The 
primary particle size of a ND ranges from 4 to 5 nm [1,7,8], with a chemically inert diamond 
core and a shell comprising sp
2
-hydridized carbon structures [9]. Various oxygen-containing 
functional groups are found on the surface of NDs [8,10,11], opening the potential for their 
conjugation with biochemical moieties. Surface modifications of NDs can be achieved through 
either a physical or a covalent (amide or ester bonding) interaction. Physical adsorption of NDs 
has been widely accomplished using toxins [12], proteins [13,14], chemotherapeutic drugs 
[5,6,15], and nucleic acids [16,17]. Carboxylic [18,19] and nitrogen-containing [20] functional 
groups have been successfully grafted onto NDs using a radical generation mechanism, while 
alkyl-, amino-, and amino acid-functionalized diamonds have been created through the chemical 
modification of fluorinated NDs with alkyl lithium, ethylenediamine, or glycine ethyl ester 
hydrochloride, respectively [21]. Moreover, NDs have also been functionalized with amino acids 
[22] and alkyl chains [23] via covalent bonding. 
NDs have been found to be biocompatible with various cell lines [15,24,25], and they 
exhibit lower cytotoxicity than other carbon-based nanomaterials such as single- and multi-
walled carbon nanotubes, and carbon black [24,25]. As such, they have been assessed for their 
ability to act as vectors for the intracellular delivery of drugs and biochemical molecules. It has 
been shown that the hydrophilic nature of NDs is responsible for improving the aqueous 
solubility of chemotherapeutic and anti-inflammatory drugs that have initially showed poor 
solubility in water [26]. Indeed, chemotherapeutic drugs such as doxorubicin [5] and 10-
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hydroxycamptothecin [6] have been successfully delivered into cancer cells after being bound to 
NDs. This carbon nanomaterial has also been envisioned as a suitable vector for gene therapy, 
and polymer-coated NDs have been shown to improve the delivery of plasmid DNA (pDNA) 
[16] and small interfering RNA (siRNA) [17] into cellular systems. Contrary to self-assembling 
nanoparticles, NDs are attractive for use in these applications because of their ability to resist 
biological environmental changes, which could improve the overall delivery of the attached 
biomolecules. 
Despite the promise NDs show as vectors for delivering small chemical drugs and large 
biotechnology products, it remains a challenge to obtain nano-sized ND particles in laboratory 
and industrial settings owing to their strong tendency to assemble into micron-sized aggregates 
when dispersed in a polar liquid medium. As these aggregates have the potential to block 
capillaries, which could lead to toxic effects in the body [27], the maintenance of dispersion 
stability of NDs is a key requirement when developing drug delivery formulations. One way in 
which dispersion stability can be improved is through the use of chemical modifications such as 
fluorination [21] and biotinylation [28]. These methods have been shown to reduce the size of 
ND aggregates from micrometer sizes to 160 [21] and 170 nm [28], respectively. While a variety 
of mechanical disaggregation approaches have also been explored, stirred media milling and 
bead-assisted probe sonication were the most successful in achieving high dispersion stability 
and producing single-digit nanometer particle sizes [29]. However, while primary-sized NDs 
may be attained by high-energy bead-assisted probe sonication, the potential for the 
contamination of samples with sonotrode material when using this technique [29] is unacceptable 
in life science applications. To the authors’ knowledge, no previous studies have examined the 
disaggregation of NDs to particles less than 50 nm in size using a simple mechanochemical 
technique that can be applied at a laboratory level. Therefore, the purpose of this study was to 
generate nanosized, amino acid–functionalized particles through the covalent modification of 
NDs with lysine using conventional bath sonication. These functionalized NDs were found to 
have the ability to bind nucleic acids through electrostatic interactions and the potential to act as 
vectors for carrying genetic materials into cellular systems, using aqueous medium. 
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 Material and Methods 4.2
4.2.1 Chemicals 
Pharmaceutical-grade (ND98) carboxylic acid–functionalized NDs with an average 
particle size of 5 nm were purchased from Dynalene Inc (Whitehall, PA). Tosoh Corporation 
(Grove City, OH) graciously provided YTZ
®
 grinding media (0.05 mm). Dry 
dimethylformamide (DMF), 4M hydrochloric acid (HCl) (in dioxane) and ethidium bromide 
solution (∼1% in water) were obtained from Sigma-Aldrich (Oakville, ON, Canada). Boc-
lysine(Boc)-OH, Fmoc-NH2(CH)3NH2⋅HCl, diisopropylethylamine (DIPEA), piperidine, and 
HATU [N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate] were 
obtained from Chem-Impex International, Inc. (Wood Dale, IL). Dichloromethane (DCM) (high-
performance liquid chromatography grade) was purchased from Thermo Fisher Scientific 
(Waltham, MA) and was dried using a solvent purification system (MBraun Incorporated, 
Stratham, NH). Thionyl chloride was acquired from Alfa Aesar (Ward Hill, MA). The 
pGTCMV.IFN-GFP plasmid (encoding for interferon gamma and green fluorescent protein 
genes) [30] was used as a model plasmid for examining the binding properties of NDs. Anti-GFP 
siRNA was purchased from Ambion
®
 (Life Technologies Inc, Burlington, ON, Canada). Gibco
®
 
UltraPure DNase/RNase-free water was obtained from Invitrogen (Life Technologies Inc, 
Burlington, ON, Canada). All chemicals were at 99% purity. 
4.2.2 Preparation and Functionalization of NDs with Lysine 
Unless otherwise stated, all reactions (Figure 4.1) were carried out under a nitrogen 
atmosphere using standard Schlenk techniques. Ultrasonication was performed using a bath 
sonicator in some steps of the reaction scheme in order to improve the accessibility of chemical 
reagents to the surfaces of the nano-sized particles. 
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Figure 4.1: Preparation and functionalization of nanodiamonds with lysine in the presence 
of a 3-carbon-length linker. 
 
Preparation and functionalization of nanodiamonds (NDs) with lysine in the presence of a three-
carbon-length linker: (A) synthesis of compound 1 [N′-(Nα,Nε-bis-Boc-lysyl),N″-(Fmoc)-
diaminopropane], reagents, and solvents – Fmoc-NH(CH2)3NH2 ⋅ HCl, HATU [N,N,N′,N′-
tetramethyl-O-(7-azabenzotriazol-1-yl) uronium hexafluorophosphate], diisopropylethylamine, 
and dimethylformamide (DMF); (B) Fmoc deprotection, reagents, and solvents – 50% (v/v) 
piperidine-DMF; (C) reoxidation of pristine carboxylated NDs, reagents – concentrated sulfuric 
acid and concentrated nitric acid, and preparation of acid chloride–functionalized NDs, reagents 
– thionyl chloride; (D) synthesis of Boc-protected lysine-functionalized NDs, solvent – DMF; 
(E) deprotection of Boc on lysine-functionalized NDs, reagents, and solvents – hydrochloric acid 
and dichloromethane. 
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Step A: synthesis of N′-(Nα,Nε-bis-Boc-lysyl),N″-(Fmoc)-diaminopropane 
In a dry Schlenk flask, Boc-lysine(Boc)-OH (8.661 mmol) was dissolved in dry DMF (15 
mL), followed by the addition of HATU (10.82 mmol) and DIPEA (17.97 mmol). The reaction 
mixture was then stirred for 15 minutes before the addition of a 10 mL solution of Fmoc-
NH(CH2)3NH2 ⋅ HCl (9.925 mmol) and DIPEA (10.92 mmol) in DMF. After 18 hours, DMF 
was removed from the reaction mixture under high vacuum, and the sample was dissolved in 
DCM (100 mL) and extracted with a saturated aqueous solution of sodium bicarbonate (4 × 100 
mL). The organic phase was dried with sodium sulfate before removing the DCM under vacuum. 
Upon further purification by column chromatography (Silica Gel 60, EMD Inc, Mississauga, 
ON, Canada) using a methanol-chloroform (1:9, v/v) solvent system, a pale yellow solid 
compound, N-(N
α
,N
ε
-bis-Boc-lysyl),N″-(Fmoc)-diaminopropane (hereafter called compound 1), 
was obtained with a yield of 79%. 
Step B: Fmoc deprotection of compound 1 
The removal of Fmoc from compound 1 was carried out using 300 mg of the compound 
and 10 mL of a 50% (v/v) piperidine-DMF mixture. The recovered compound (hereafter called 
compound 2) was used in step D without further purification. 
Step C: reoxidation of NDs and preparation of acid chloride–functionalized NDs 
In order to optimize the surface functionalization of the pristine carboxylated NDs 
(pNDs), they were reoxidized in a mixture of concentrated nitric and sulfuric acids (1:3, v/v) 
with overnight ultrasonication [31-33]. The reoxidized NDs (rNDs) were subsequently dialyzed 
with water using a cellulose membrane with an average pore radius of 2.4 nm until neutral pH 
was achieved, and then they were freeze-dried. To promote amide bond formation between the 
NDs and compound 2, the surface carboxylic acid groups of the rNDs were converted into more 
reactive acyl chloride functional groups using an excess of thionyl chloride [34-36] in the 
presence of YTZ
®
 grinding media. This mixture was ultrasonicated at a frequency of 25 kHz in a 
bath sonicator (Transsonic TI-H-5 Ultrasonicator; Elma Hans Schmidbauer GmbH and Co KG, 
Singen, Germany) for 22 hours, refluxed for 5 hours at 70°C, and ultrasonicated for 48 hours. 
Finally, the sample was dried overnight under high vacuum. 
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Steps D and E: preparation of lysine-functionalized NDs 
Compound 2 was dissolved in 10 mL of DMF and added to the acid chloride–
functionalized NDs (100 mg) suspended in 5 mL of DMF. The heterogeneous mixture was 
refluxed for 45 minutes at 75°C, ultrasonicated for 72 hours, and lyophilized. Boc removal (step 
E, Figure 4.1) was achieved by suspending the Boc-protected lysine-functionalized NDs (fNDs) 
in 10 mL of DCM and 10 equivalents of HCl (4 M in dioxane) [37] for 90 minutes. This 
produced positively charged fNDs capable of electrostatic interactions with the negatively 
charged phosphate groups of DNA. The fNDs were dialyzed with ethanol followed by water, 
using a cellulose membrane with an average pore radius of 2.4 nm, before being freeze-dried. 
4.2.3 Nuclear Magnetic Resonance and Mass Spectroscopic Characterization of 
Compound 1 
Proton nuclear magnetic resonance (
1
H NMR) spectra were recorded on a Bruker 500 
MHz Avance spectrometer (Bruker BioSpin, Milton, ON, Canada). Chemical shifts for 
1
H NMR 
are reported in ppm in reference to the residual 
1H resonances of deuterated chloroform at δ 7.26. 
Mass spectrum was obtained using the QSTAR
®
 XL MS/MS System with electrospray 
ionization source (ESI-Q-TOF) (Applied Biosystems, Toronto, ON, Canada). 
4.2.4 ND Dispersions 
NDs (2 mg/mL) in reverse osmosis-purified water (Millipore, Milford, MA) were 
ultrasonicated at a frequency of 25 kHz for 4 hours and centrifuged at 5200 g for 6 minutes. The 
resulting dispersions were used for Raman spectroscopy, atomic force microscopy (AFM), gel 
electrophoresis, and zeta potential and size distribution measurements. For the dispersion 
stability experiment, the ND samples were sonicated for 20 minutes and allowed to settle for 3 
days at room temperature without centrifugation. 
4.2.5 Raman Spectroscopic Measurements 
Raman spectroscopic measurements were carried out using a Renishaw Invia Reflex 
microscope (Renishaw Inc, Chicago, IL) fitted with a 514.5 nm argon ion laser (Spectra-
Physics
®
 163-M42-010 Spectra Physics
®
, Santa Clara, CA) and 1800 line/mm grating. Aqueous 
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dispersions of NDs were dropped onto a gold-coated silicon wafer (Platypus Technologies, 
Madison, WI) and allowed to dry. A Leica N PLAN Objective (Leica Microsystems, Buffalo 
Grove, IL) 50× with a numerical aperture of 0.75 was used to focus the sample, and 
backscattered Raman signals were detected using a Peltier-cooled charge-coupled device. 
Instrument calibration was verified using an internal silicon wafer, measured at 520 cm
−1
.  
The Raman spectra of NDs and compound 1 were acquired in the static scanning mode. Baseline 
correction was performed using Renishaw WiRE software (v3.2; Renishaw Inc). 
4.2.6 Infrared Spectroscopy 
Infrared (IR) spectra of all materials were recorded on a Bruker IFS 66v/S Fourier 
transform spectrometer (Bruker Optics, Billerica, MA) in the mid-IR range using a liquid 
nitrogen–cooled mercury cadmium telluride detector at the Canadian Light Source, University of 
Saskatchewan, Saskatoon, SK, Canada. All sample measurements were carried out in the solid 
state using pelletized, homogeneous powder dispersions of the materials in a potassium bromide 
matrix. For compound 1, a PIKE MIRacle™ Single Reflection ATR (PIKE Technologies, 
Madison, WI) accessory was used in order to avoid potential pressure-induced changes. In all 
cases, 512 individual interferograms were averaged for both the background and the sample 
measurements from which the absorbance spectra were calculated. 
Data analysis was performed with the Bruker OPUS software package (v6.5; Bruker 
Optics). Baseline correction was performed on all raw absorbance spectra using the built-in 
concave rubber band correction routine (number of baseline points: 32; number of iterations: 2) 
to strictly avoid the introduction of any artificial features into the spectra. 
4.2.7 Size and Zeta Potential Measurements 
Particle size and zeta potential measurements were obtained using a Malvern Zetasizer 
Nano ZS instrument (Malvern Instruments Ltd, Malvern, Worcestershire, UK). The size 
distribution of NDs in water was obtained by measuring the light scattered (θ = 173°) by 
particles (dynamic light scattering, DLS) illuminated with a laser beam, using the CONTIN 
algorithm to analyze the decay rates that are a function of the translational diffusion coefficients 
of the particles, D. The measured data are reported in volume distribution. The hydrodynamic 
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radius, RH, of the particles was estimated using the Stokes-Einstein equation (RH =kT/6πηD), 
where k is the Boltzmann constant, T is the temperature, and η is the viscosity of the solution. 
This analysis gives an estimate of size based upon the hydrodynamic radius of spherical particles 
having a translational diffusion coefficient equivalent to the actual particles. Size distribution 
values were derived from three measurements, each consisting of a minimum of ten individual 
runs. Zeta potential measurements were based upon laser Doppler electrophoresis and phase 
analysis light scattering analysis. The reported zeta potentials are the average of three 
measurements, each derived from a minimum of ten individual runs. 
4.2.8 AFM 
AFM images were obtained in intermittent contact mode using an atomic force 
microscope (Agilent 4500; Agilent Technologies, Inc., Chandler, AZ) equipped with a silicon 
cantilever (T190R; Nanoscience Instruments, Inc., Phoenix, AZ). The specifications of the 
silicon cantilever include a force constant of approximately 45 N/m and a resonant frequency of 
approximately 190 kHz. A small volume (25 µL) of ND dispersion samples was dropped onto a 
freshly prepared poly-L-lysine-coated mica substrate and allowed to incubate for 1 minute. The 
substrate was then rinsed with purified water and dried gently using a stream of nitrogen gas. 
The amplitude range was between 1 and 1.5 V for all measurements, while the amplitude ratio 
for set point to free air oscillation was 0.80. Ambient conditions were maintained throughout the 
experimental procedure, and the scan rate used for image acquisition ranged from 0.5 to 1 lines 
per second (512 pixels per line). Line scan profiles were obtained for three particles from each 
sample, and the reported particle sizes were determined from the particle height (SPIP, v5.1.6; 
Image Metrology A/S, Lyngby, Denmark). 
4.2.9 Thermogravimetric Analysis 
Thermogravimetric analysis was carried out using a TGA Q50 (TA Instruments-Waters 
LLC, New Castle, DE). The furnace tube carrying the sample was heated to 450°C, and the 
percentage weight loss was obtained as a function of the temperature. The surfaces of the pNDs 
and rNDs were considered dominated by carboxylic acid functional groups, and surface loading 
was calculated using the following equation: 
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 .............................(4.1) 
Any loss in weight that occurred below 115°C was attributed to water and was excluded from 
estimates of surface loading. 
4.2.10 Agarose Gel Electrophoresis 
Electrophoresis was performed in 1% (for pDNA) or 2% (for siRNA) agarose gels 
prepared with tris-acetate ethylenediaminetetraacetic acid buffer and ethidium bromide at a final 
concentration of 1 µg/mL. The amounts of pDNA and siRNA in each sample were 500 and 400 
ng, respectively. Complexes of fNDs-pDNA and fNDs-siRNA with different weight ratios 
(fNDs:nucleic acid component ranging from 1:1 to 50:1) were prepared in ultrapure water and 
incubated for 30 minutes at room temperature. Uncomplexed pDNA and siRNA were used as 
standards. All samples were loaded into the gel using 30% glycerol and were subjected to 
electrophoresis at 100 V using a Bio-Rad PowerPac HC electrophoresis apparatus (Bio-Rad 
Laboratories, Inc., Mississauga, ON, Canada) for 1 hour for pDNA or 45 minutes for siRNA. 
The gels were then imaged using an AlphaImager
®
 imaging system (Alpha Innotech 
Corporation, San Leandro, CA) to detect ultraviolet fluorescence. 
4.2.11 Size and Zeta Potential Measurements of fND-pDNA and fND-siRNA 
Complexes 
Size and zeta potential measurements of fND-genetic material complexes formed at weight 
ratios in the range between 1:1 and 50:1 were performed using the Zetasizer Nano ZS (Malvern 
Instruments Ltd). Different sets of samples were prepared for analysis of size and zeta potential 
using the same sample preparation technique as described for agarose gel electrophoresis assay. 
Each reported value was obtained from the Z-average size, and each value is the average of four 
measurements, each consisting of a minimum of ten individual runs. 
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 Results and Discussion 4.3
4.3.1 Synthesis of fNDs 
The synthesis of the lysine linker intermediate (compound 1) and its subsequent covalent 
functionalization with NDs was performed (Figure 4.1). The 
1
H NMR spectrum of compound 1 
was used to established its structure: 
1
H NMR (500 MHz, deuterated chloroform) δ 7.76(d, J = 
7.5, 2H, fluorenyl), 7.61 (d, J = 7.4, 2H, fluorenyl), 7.39 (t, J = 7.5, 2H, fluorenyl), 7.31 (t, J = 
7.4, 2H, fluorenyl), 6.67(s, 1H, NH), 5.48(s, 1H, NH), 5.23(s, 1H, NH), 4.67(s, 1H, NH), 4.38(d, 
J =7.0, 2H, fluorenyl-CH2), 4.21(t, J = 7.0, 1H, fluorenyl-CH), 4.04(s, 1H), 3.28 (m, 2H), 
3.20(m, 2H), 3.10(m, 2H), 1.63–1.82(m, 4H), 1.48 (m, 2H), 1.43(s, 18H, Boc-(CH3)6), 1.37(m, 
2H) (Figure S 4.1). The successful synthesis of compound 1 was also confirmed by mass 
spectroscopic measurements: electrospray ionization mass spectrometry mass-to-charge ratio 
calculated for C34H48 N4O7: 624.3523 [M], found 625.3603 [M+H]
+
 (Figure S 4.2). 
4.3.2 Surface Functionalization Assessed by Raman Spectroscopy, IR 
Spectroscopy, Zeta Potential, and Thermogravimetric Measurements 
To provide evidence of functionalization of NDs with the lysine linker, Raman 
spectroscopy of pNDs, rNDs, fNDs, and compound 1 was performed (Figure 4.2). The pNDs 
showed the signature peak of diamond at 1326 cm
−1
, which is downshifted in frequency 
compared with the 1332 cm
−1
 Raman peak assigned to bulk diamond [38]. This frequency shift 
could be attributed to the smaller size of NDs, as explained by the phonon confinement model 
[39,40]. Furthermore, the existence of the diamond peak at ∼1326 cm−1 after the reoxidation 
process suggests that the intrinsic diamond structure was unaltered by the harsh acidic oxidation 
conditions. A broad peak was also observed at 1617 cm
−1
 on the pND spectra, which could have 
arisen because of overlapping signals from the in-plane stretching of the sp
2
 carbon (G-mode) at 
∼1590 cm−1, oxygen-hydrogen (O-H) bending at ∼1635 cm−1, and carbon-oxygen double bond 
stretching of the carboxylic acid group at ∼1740 cm−1 [41]. The suppression of the D-band of 
graphitic carbon (∼1410 cm−1) in the Raman spectra of pristine and reoxidized NDs supports the 
existence of high ratios of sp
3
/sp
2
 carbon in NDs [42]. After reoxidation, the emergence of a 
prominent band at ∼1630 cm−1 was accompanied by a decrease in the 1590 cm−1 band of 
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graphitic carbon, supporting the use of mineral acids in the oxidation of graphitic carbon. Raman 
spectroscopy was not used to monitor carboxylic acid vibrations in any of the samples. 
The Raman spectrum of compound 1 revealed noticeable peaks of carbon-hydrogen (C-
H) deformation at ∼1481 cm−1, amide III at ∼1295 cm−1, and amide I at ∼1611 cm−1, with a 
weak shoulder representing amide II observed at ∼1580 cm−1. It is important to note that the fND 
spectrum was acquired by a single scan, as additional laser scanning resulted in burning of the 
fNDs. In comparison with the Raman spectrum of compound 1, the Raman spectrum of the fNDs 
exhibited amide I (∼1612 cm−1), amide II (∼1582 cm−1), amide III (∼1299 cm−1), and C-H 
deformation (∼1482 cm−1) peaks, indicating that the functionalization had been successful. The 
Raman peak of fNDs at 1299 cm
−1
 is very broad in comparison with the corresponding peak of 
compound 1 because of interference from the diamond signal. Furthermore, the covalent 
modification of the NDs with the lysine linker, which has a much higher mass than carbon, 
caused a further downshift in the frequency of the diamond signal in fNDs. 
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Figure 4.2: Raman spectra of nanodiamonds and compound 1 
 
Baseline-corrected static scan Raman spectra of the pristine carboxylated nanodiamonds (pNDs), 
reoxidized nanodiamonds (rNDs), lysine-functionalized nanodiamonds (fNDs), and compound 1 
[N′-(Nα,Nε-bis-Boc-lysyl),N″-(Fmoc)-diaminopropane] using a 514.5 nm excitation source. A 
total of 128 accumulations were collected for pNDs and rNDs, while the spectrum of fNDs was 
obtained from a single acquisition.  
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Overall, the Raman spectra obtained in this study support the successful formation of 
fNDs; however, as the Raman cross section is smaller than the fluorescence cross section, it is 
likely that fluorescence swamps the Raman signals. Hence, to strengthen the evidence of 
successful functionalization, IR spectroscopy, a complementary technique to Raman 
spectroscopy, was performed at various stages of functionalization, including on compound 1 
(Figure 4.3A). Band positions are indicated by the second derivative curves (Figure 4.3B). The 
ND spectra showed that characteristic bands at ∼1045 cm−1 and ∼1262 cm−1 due to vibrations of 
ether-like groups [43] might arise from the covalent bonding of inter-particular carboxylic and/or 
hydroxyl groups, as well as bands in the C-H stretching region at ∼2900 cm−1 due to vibrations 
arising from the C-H bonds present on the surface of the NDs. In fact, a very broad IR spectrum 
ranging from 1000 to 1500 cm
−1
 is identified as the “fingerprint region” of NDs in the literature 
[42]. It is important to note that all ND spectra were found to have features in the carbonyl 
region (∼1760 cm− 1), suggesting that the raw material was already somewhat oxidized. The 
peaks at ∼1630 cm−1 (O-H bending) and ∼3400 cm−1 (O-H stretching) may have originated 
because of either the water adsorbed onto the NDs/potassium bromide or the presence of 
covalently bonded hydroxyl functional groups on the surface of the NDs. 
Comparing the spectra of fNDs with those of pNDs and rNDs, it is evident from both the 
peak height and shape of the band located at ∼1630 cm−1 that the functionalization reaction was 
successful. The presence of an amide I band from ∼1640 to 1690 cm−1 and an amide II shoulder 
from ∼1510 to 1580 cm−1 in the fND spectrum provide further evidence of functionalization. 
These bands were also observed in the compound 1 spectrum at a slightly higher frequency. The 
peak at ∼730 cm−1 in the spectra of both fNDs and compound 1 is associated with the rocking 
mode of hydrocarbons with more than four methylene groups [44], while a methylene 
deformation band can be observed at ∼1465 cm−1. A combination of the spectra of the two 
starting materials (rNDs and compound 1) was recognizable in the C-H stretching region of the 
second derivative spectra (Figure 4.3B, red oval shape), further verifying the lysine 
functionalization of NDs. 
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Figure 4.3: Infrared spectra of nanodiamonds and compound 1 
 
Baseline-corrected absorbance and attenuated total reflectance: (A) infrared spectra of the 
pristine carboxylated nanodiamonds (pNDs), reoxidized nanodiamonds (rNDs), lysine-
functionalized nanodiamonds (fNDs), and compound 1 [N′-(Nα,Nε-bis-Boc-lysyl),N″-(Fmoc)-
diaminopropane]; (B) second derivatives of all spectra. A total of 512 individual interferograms 
were collected and averaged for each sample. The featureless region between wave numbers of 
2700 and 1900 cm
−1
 is not shown.  
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The successful functionalization of NDs with lysine was also confirmed by the zeta 
potential measurements (Table 4.1). The pNDs showed a negative zeta potential of −21.1 mV, 
suggesting that negatively charged surface functional groups such as carboxylate were present. 
After reoxidation, the mean zeta potential shifted to −23.7 mV, indicating a slight increase in the 
density of negatively charged surface groups. As expected, the lysine-modified NDs showed a 
positive zeta potential of +48.9 mV, demonstrating the predominance of a large number of 
positively charged (amine) groups on their surfaces. 
Thermogravimetric analyses were performed to provide quantitative estimates of the 
surface loading of functional groups attached to the NDs. The thermograms of the pNDs and 
rNDs did not show any considerable weight loss in the temperature range of 30°C to 440°C, 
indicating that NDs are thermally stable in this range (Figure 4.4). The surface loading of the 
pNDs, rNDs, and fNDs was calculated (Table 4.2) from their respective thermograms. Providing 
that the surfaces of pNDs and rNDs are dominated by carboxylate groups, the estimated surface 
coverage was 0.35 mmol g
−1
 for the pNDs and 1.0 mmol g
−1
 for the rNDs, while the fNDs 
demonstrated surface loading of 1.7 mmol g
−1
 of ND. This coverage is greater than was found in 
a previously reported study of the covalent functionalization of long-chain alkyl groups on the 
surface of NDs (0.3–0.4 mmol g−1) [23]. The high surface functionalization confers high nucleic 
acid–binding capacity to the nanomaterial. 
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Table 4.1: Zeta potential measurements of nanodiamonds 
 
Sample Zeta Potential (mV) in Millipore water 
pNDs -21.1 ± 0.2 
rNDs -23.7 ± 0.5 
fNDs +48.9 ± 0.1 
 
Each value represents the mean ± standard deviation of three measurements with n ≥ 10 
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Figure 4.4: Thermograms of samples of nanodiamonds.  
 
Thermograms of pristine carboxylated nanodiamonds (pNDs), reoxidized nanodiamonds (rNDs), 
and lysine-functionalized nanodiamonds (fNDs) shows highest % weight loss in fNDs followed 
by rNDs and pNDs. 
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Table 4.2: Surface loading of nanodiamonds as calculated from their respective 
thermograms 
 
 
 
 
 
 
 
Note: Weight loss below 115ºC is excluded 
Sample Surface Loading (mmol/g) 
pNDs 0.35 
rNDs 1.00 
fNDs 1.70 
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4.3.3  Dispersion of NDs in Aqueous Medium and AFM Imaging 
For biomedical applications, the stability of the biomaterial in aqueous medium is of 
paramount importance, as aggregation can lead to toxic effects in biological systems. In this 
study, the pND, rND, and fND samples were dispersed in water and the stability of the resultant 
hydrosols was monitored for 3 days. While sedimentation of the pND and rND hydrosols was 
observed to occur within the first 5 minutes of incubation, fNDs remained stable even after 3 
days (Figure 4.5). This was in agreement with the results of the authors’ zeta potential 
measurements, which also indicated that fNDs have colloidal stability in water. According to the 
DLVO theory (Derjaguin-Landau-Verwey-Overbeek), repulsive forces dominate among particles 
in systems with a zeta potential higher than 30 mV (49 mV for the fNDs), which prevents 
aggregation and flocculation of the colloidal system [45].  
The high aqueous dispersibility of fNDs may be explained by the greater hydrophilicity 
of the lysine hydrochloride functional groups found on their surfaces [46], as well as inter-
particle repulsion due to the positively charged amine groups of lysine. On the other hand, the 
sedimentation of pNDs and rNDs is most likely due to van der Waals’ forces, dipole-dipole 
interactions, and/or hydrogen bonding between the surface functional groups. A similar 
dispersion behavior has been shown to occur with adenosine-functionalized multi-walled carbon 
nanotubes, which exhibit greater aqueous solubility than pristine, reoxidized forms [32]. 
Particle size is also considered to be an important parameter in the development of bio-
nanomaterials. Therefore, hydrodynamic particle size measurements were carried out in this 
study to gain more insight into the suitability of fNDs for use in gene delivery applications 
(Figure 4.6). The pNDs were found to have a very wide size distribution (polydispersity index 
[PDI] = 0.56) when dispersed in aqueous medium, with a major fraction of the particles having 
size distributions centered at 1281 nm. Reoxidation did not improve the particle dispersibility 
considerably; while a shift towards smaller size with a peak at 531 nm was observed, the 
broadness in the size distribution was maintained (PDI = 0.59). No NDs smaller than 50 nm in 
diameter were detected in either pND or rND samples.   
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Figure 4.5: Dispersion stability of 2 mg/mL nanodiamonds samples in water.  
 
Dispersion of nanodiamonds (NDs) in water after 20 minutes of conventional bath sonication 
and a 3-day incubation. From left to right: pristine nanodiamonds (pNDs), reoxidized 
nanodiamonds (rNDs), and lysine-functionalized nanodiamonds (fNDs).   
pNDs rNDs fNDs 
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Figure 4.6: Size distribution curves of nanodiamonds samples. 
 
Size distributions of pristine carboxylated (pNDs), reoxidized (rNDs), and lysine-functionalized 
nanodiamonds (fNDs) in water, as measured by dynamic light scattering. Each curve is derived 
from three measurements with n ≥ 10.  
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In addition to the physical inter-particle interactions that cause agglomeration of pristine 
and reoxidized NDs, the surface carboxylate groups can also result in the formation of tightly 
bound aggregates via anhydride bond formation [22]. In contrast, when the size of the fNDs was 
examined, the surface functionalization was found to result in a remarkable reduction in 
aggregate size, with the majority of particles centering at 21 nm. A narrower size distribution 
(PDI =0.25) was also observed when compared with the pND and rND particle distributions. The 
fNDs in this study were also found to have considerably smaller hydrodynamic radii than those 
obtained in a previous study that functionalized NDs with glycine through a silane linker (peak at 
>350 nm) [22]. The disaggregation of fNDs also contributes to their dispersion stability in 
aqueous media. 
AFM was used to determine the topographic features (Figure 4.7A) and size (Figure 
4.7B) of pNDs (i), rNDs (ii), and fNDs (iii). Since substrate surface features and drying could 
cause aggregation of the particles, the height rather than the diameter is reported for particle size. 
The pNDs formed irregularly shaped aggregates of 40–80 nm, while the rNDs appeared to be 
round with a comparatively smaller aggregate size of 20–60 nm. In agreement with the DLS 
measurements, AFM images provided visual evidence for the disaggregation of NDs after their 
functionalization with the lysine linker (Figure 4.7A, iii). The particles of fNDs were found to be 
3–5 nm in size. Besides aggregation on a solid mica surface, the environment of the sample and 
the principle of the measurement technique can also influence the size determination of particles, 
as can be observed in the differences in particle sizes determined by DLS and AFM. DLS 
measures the average hydrodynamic radius of nanoparticles in liquid medium under the 
assumption that they are spherical in shape, while AFM measures the height and diameter of 
individual particles devoid of their native environment. The different principles utilized by these 
two techniques for size determination have also been considered to be a cause of size variation in 
an earlier study [47]. 
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Figure 4.7: Atomic force microscopic images and line-scan profiles of nanodiamonds 
samples.  
 
(A) Intermittent contact mode atomic force microscopy (AFM) of ND samples and (B) line-scan 
profiles of the particles indicated in each image. From left to right: (i) pristine nanodiamonds 
(pNDs), (ii) reoxidized nanodiamonds (rNDs), and (iii) lysine-functionalized nanodiamonds 
(fNDs). Line scan profiles were obtained for three particles from each sample, and the reported 
particle sizes were determined from the particle height. 
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4.3.4  Binding of fNDs to Nucleic Acids 
As the nanosize, positive zeta potential, and hydrophilic properties of fNDs suggest that 
they may be suitable for use in biomedical applications, the applicability of fNDs as non-viral 
vectors was evaluated by examining their ability to bind and protect pDNA and siRNA. Weak 
binding can lead to the disruption of vector–nucleic acid complexes by negatively charged 
protein molecules, leading to inefficient gene delivery [48]. Therefore, the binding stability of 
complexes is essential for the protection of genetic material against enzymatic degradation and 
the production of high levels of gene expression in cellular systems [30]. In this study, the 
binding efficacy of the fNDs for genetic material was examined by carrying out gel 
electrophoresis assays on a series of fNDs:pDNA (Figure 4.8A) and fNDs:siRNA (Figure 4.8B) 
weight ratios. The naked pDNA revealed two major bands (Figure 4.8A), corresponding to the 
two different forms of pDNA: a highly mobile supercoiled form and a lesser mobile band 
representing the circular form. The complexes obtained by using equal weight ratios of fNDs and 
pDNA were not stable, as the migration of pDNA was not hindered (Figure 4.8A). However, no 
pDNA bands were detected at fNDs:pDNA weight ratios of 5:1 and above, indicating that the 
formation of a complex between the pDNA and the fNDs hampered its migration towards the 
anode. For siRNA (Figure 4.8B), the trend of binding was found to be similar; however, complex 
formation was comparatively less efficient than that observed with pDNA, as siRNA was 
detected in its free form at weight ratios of 5:1 (Figure 4.8B) and 10:1. The band intensity 
gradually decreased with an increase in the amount of fNDs, and only a negligible amount of 
siRNA was detected in its free form at weight ratios of 20:1 and higher. 
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siRNA 1:1    5:1    10:1   15:1  20:1  25:1   30:1  35:1   40:1  45:1  50:1 empty 
 
  
 
 
 
 
                                                              
 
 
                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: Agarose gel electrophoresis of lysine-functionalized nanodiamonds with 
plasmid DNA and small interfering RNA. 
 
Results of agarose gel electrophoresis of (A) lysine-functionalized nanodiamonds-plasmid DNA 
(fNDs-pDNA) and (B) lysine-functionalized nanodiamonds-small interfering RNA (fNDs-
siRNA) complexes (“diamoplexes”) with increasing weight ratios of fNDs to nucleic acid.  
A 
B 
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As the size of a nanomaterial–nucleic acid complex can also have a pronounced impact 
on transfection efficacy, a delivery agent should condense genetic material to prevent its 
degradation by nucleases and promote cellular internalization. A size in the range of 100–300 nm 
is considered optimal for producing efficient transfection [49]. In addition to appropriate size, the 
surface charge of transfection complexes also governs the intracellular delivery of transgenes, 
and an overall positive charge is desired in order to promote internalization across the negatively 
charged cell surface by means of favorable electrostatic interactions [50]. In order to optimize 
these parameters, the size and zeta potential of particles formed at various weight ratios of 
fNDs:pDNA and fNDs:siRNA were measured. An increase in the weight proportion of fNDs to 
genetic material from 1:1 to 50:1 resulted in a shift in zeta potential from negative to positive, 
indicating that no free genetic material was available at higher weight ratios. The fND:pDNA 
particles exhibited considerable aggregation (precipitate) at a 6:1 weight ratio because of neutral 
zeta potential (Figure 4.9A), while this neutral zeta potential was reached at a much higher 
weight ratio (20:1) in the fND-siRNA system (Figure 4.9B). With an increase in ratio from 10:1 
to 50:1, particle size was found to stabilize around 110 nm for fND-pDNA complexes (Figure 
4.9A) and was less than 280 nm for the fND-siRNA complexes (Figure 4.9B). In the case of the 
fND-pDNA complexes, the zeta potential reached 40–50 mV at ratios of 30:1 and beyond, while 
a positive zeta potential of nearly 30 mV was attained at a ratio of 50:1 in fND-siRNA 
complexes. These results demonstrate the ability of fNDs to condense pDNA and form 
complexes with pDNA and siRNA within the size range suitable for producing efficient 
transfection. These size and zeta measurements correlate well with those from the gel 
electrophoresis assay, indicating that the retardation of nucleic acid material coincides with the 
electroneutrality of the “diamoplexes.”  
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Figure 4.9: Size and zeta potential measurements using various weight ratios of lysine-
functionalized nanodiamonds with plasmid DNA and small interfering RNA. 
 
Size and zeta potential measurements using various weight ratios of (A) lysine-functionalized 
nanodiamonds-plasmid DNA (fNDs:pDNA) and (B) lysine-functionalized nanodiamonds-small 
interfering RNA (fNDs:siRNA).  
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In this study, the ratio of lysine linker present per base pair of pDNA and siRNA was also 
calculated based on the surface loading of the fNDs and the number of base pairs of nucleic acids 
(Table 4.3). The differences in the binding behavior of these two genetic materials to the fNDs 
can be attributed to structural differences of the circular pDNA having 5805 base pairs and linear 
siRNA having only 21 base pairs. The formation of complexes between nanoparticles and siRNA 
has also been observed to occur at a higher weight ratio than nanoparticles and pDNA in 
previous studies involving chitosan nanoparticles [51,52]. A suggested model for the formation 
of complexes between fNDs and pDNA or siRNA, taking into account the binding behavior, 
size, and zeta potential measurements of the complexes, as well as the structural peculiarities of 
the genetic materials themselves, is shown in Figure 4.10. In this model, the pDNA is thought to 
form a spherical nanostructure with positively charged fNDs, while the structural configuration 
of linear siRNA with fNDs is rather complex, involving several linear siRNA sequences. 
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Table 4.3: Ratios of lysine residues on the nanodiamonds per base pair of genetic material 
as calculated from surface loading measurements  
,  
 
 
 
 
 
 
 
 
Note: NR, not reported. 
 
 
 
 
Weight ratios of 
fNDs:genetic material 
Calculated lysine per siRNA 
base pair ratio 
Calculated lysine per 
pDNA base pair ratio 
1:1 1.1 1.1 
5:1 5.4 NR 
6:1 NR 6.6 
10:1 11 11 
20:1 22 22 
30:1 32 33 
40:1 43 44 
50:1 54 55 
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Figure 4.10: Schematic representation of the different binding behavior of plasmid DNA 
(pDNA) and small interfering RNA (siRNA) to positively charged lysine-functionalized 
nanodiamonds (fNDs).  
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 Conclusion 4.4
In this study, the surfaces of NDs were covalently functionalized with lysine attached to a 
three-carbon-length linker. These modified NDs exhibited surface loading of 1.7 mmol g
−1
 and 
excellent dispersibility in water, as well as showing a considerable reduction in the aggregate 
size of the particles (21 nm), as measured by DLS. AFM images confirmed the disaggregation of 
the fNDs in comparison with the carboxylated NDs. The hydrophilicity exhibited by the 
functionalized NDs in this study also provides an advantage for their use in animal and human 
systems, as water can be used as a dispersion medium. Finally, the fNDs exhibited an ability to 
bind pDNA and siRNA by forming nanosized “diamoplexes”. This property should be explored 
further to determine the applicability of fNDs as vectors for the delivery of genetic materials in 
gene therapy.  
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 Supplemental Data 4.6
Figure S 4.1: 
1
H NMR spectra of compound 1 at 500 MHz. 
Proton nuclear magnetic resonance spectra of compound 1 [N′-(Nα,Nε-bis-Boc-lysyl),N″-(Fmoc)-
diaminopropane] at 500 MHz. 
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Figure S 4.2: Mass spectrum of compound 1. 
 
Mass spectrum of compound 1 [N′-(Nα,Nε-bis-Boc-lysyl),N″-(Fmoc)-diaminopropane]. 
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                                                                                                                           Chapter 5
CELLULAR STUDIES ON NANODIAMONDS: INTERACTION WITH MAMMALIAN 
CELLS, TOXICITY AND ABILITY TO DELIVER SMALL INTERFERING RNA 
Abstract 
Nanodiamonds (NDs) are carbon based nanomaterials with an inert sp
3
 hybridized carbon 
core. The potential of lysine-functionalized NDs (fNDs) as nucleic acid delivery vehicle is 
demonstrated in the previous chapter, however, their cellular association, toxicity and ability to 
deliver siRNA needs to be assessed in vitro. In this study, Raman-fluorescence, backscattering 
and laser scanning confocal microscopy was employed to examine the cellular interaction of 
NDs. MTT cytotoxicity assay investigated the viability of cells after incubating with NDs for 24 
hours. Fluorescence activated cell sorter was used to evaluate the intracellular siRNA delivering 
efficacy of fNDs. The fNDs demonstrated successful cellular association, while remaining 
biocompatible to the cells from 4 to 250 µg/mL concentration. However, fNDs generated in this 
study were unable to improve the overall intracellular delivery of siRNA. Although fNDs 
showed cellular interaction and negligible cytotoxicity, their superior siRNA delivering ability 
remains to be established in this study.   
 Introduction 5.1
One of the basic requirements for the consideration of a material for use in delivering 
therapeutic agents into biological systems is their cellular interaction, leading to successful 
internalization. Previous studies demonstrated the ability of nanodiamonds (NDs) to be 
internalized by mammalian cells via passive diffusion, clathrin-mediated endocytosis and 
macropinocytosis [1,2]. In this study, Raman-fluorescence and elastic light scattering mapping 
were applied to explore the interaction of NDs with the human cells. The feasibility of laser 
scanning confocal microscopy to identify the localization of NDs in a human cell line using the 
autofluorescence of NDs as a detection marker was also investigated. The advantages and 
disadvantages of employing these techniques as tools for in vitro tracking of NDs are discussed. 
 In addition to the cellular interaction and consequent internalization, another crucial 
requirement of the delivery agent to be used in biological systems is their biocompatibility [3,4]. 
Although earlier studies have demonstrated negligible in vitro toxicity of NDs [3,5-9], the cell 
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type, size, surface properties and shape of nanoparticles can influence the biocompatibility [10]. 
Therefore, the cytotoxicity of pristine carboxylated nanodiamonds (pNDs) and lysine-
functionalized nanodiamonds (fNDs), with and without serum, was again tested using human cell 
line. Finally, flow cytometry was used to assess the efficacy of fNDs to deliver anti-green 
fluorescent protein (GFP) small interfering RNA (siRNA) in mammalian cells expressing GFP. 
 Materials 5.2
Hela cells (human cervical cancer cells), Eagle’s Minimum Essential Medium (EMEM), 
and Dulbecco's Modified Eagle Medium (DMEM) were obtained from American Type Culture 
Collection, VA, USA.  Hela cells expressing GFP (Hela/GFP) were acquired from Cell Biolabs, 
CA, USA. Fetal bovine serum (FBS) and 0.1 mM MEM Non-Essential Amino Acids were 
acquired from Gibco, ON, Canada. Lipofectamine
TM 
RNAiMAX and (Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) reagent were purchased from Invitrogen, ON, Canada. 
Trypsin and antibiotics were obtained from Sigma Aldrich, ON, Canada, and anti GFP siRNA 
was purchased from Ambion, ON, Canada. Cell culture plates and polystyrene petri dishes were 
purchased from Falcon BD, ON, Canada. Gold-coated silicon wafer was supplied by Platypus 
Technologies, WI, USA and coverslips were purchased from VWR International, ON, Canada. 
  Methods 5.3
5.3.1 Cell Culture 
Hela cells were grown in EMEM supplemented with 10% FBS and 1% 
antibiotic/antimycotic agents. The growth medium for Hela/GFP cells was DMEM supplemented 
with 10% FBS, 0.1 mM non-essential amino acids and 1% antibiotic/antimycotic agents. All the 
cells were grown to 70-80% confluency at 37°C in a humidified incubator supplied with 5% 
CO2. Second passage from the initiation of the frozen cell line was used for all the experiments. 
In general, no more than 12 passages from the original population were used for any of the 
experiment. In all the assays, the media of cells was replaced with fresh unsupplemented media 
one hour prior to the treatment and the cells were incubated at 37°C and 5% CO2 in a humidified 
incubator. 
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5.3.2 ND Dispersion Preparation 
Unless stated, the dispersions of NDs for all the assays were prepared in unsupplemented 
media with 4 hours of bath sonication at a frequency of 25 kHz without heating. 
5.3.3 Imaging of NDs with Cells using Raman-Fluorescence and Backscattering 
Mode Microspectroscopic Mapping 
Raman-fluorescence and backscattering mode mapping of cells incubated with NDs was 
carried out using a Renishaw Invia Reflex microscope. Pieces of the gold-coated silicon wafer 
were washed with double distilled water and 70% ethanol, and placed in the wells of 48-well 
plate. Hela cells, at the density of 10,000 cells per well were allowed to adhere to the gold 
substrate 24 hours prior to ND treatment. Then the media of each well were replaced with 200 µl 
of the ND dispersion prepared at the concentration of 200 µg/mL. After 7 hours, the media was 
supplemented with FBS to a final concentration of 10%. The cells were incubated with NDs for 
24 hours, and then washed three times with sterile phosphate buffer saline (PBS) (5 minutes 
each) using a plate shaker to remove non-internalized NDs.  Gold wafers with cells were placed 
in polystyrene Petri dish containing 2 mL of PBS. Raman-fluorescence and backscattering mode 
mapping of the cells was carried out with 514.5 nm (1800 lines/mm grating) and 1060 nm (1200 
lines/mm grating) lasers, respectively. Long working-distance 50X objective allowed the 
measurements of the cells in PBS. The instrument was calibrated using Silicon wafer measuring 
at 520 cm
-1
. The laser intensity during the Raman-fluorescence mapping was 100%, while the 
backscattering mapping was performed with 0.1% (pNDs treated cells and control) and 0.05% 
(fNDs treated cells and control) laser intensity. The lower and upper intensity limits of the Look 
Up Table, used to create the map of control and treated cells, were set manually from 3400 to 
4000 (Raman-fluorescence maps), 13500 to 38000 (backscattering maps using 0.1% laser 
intensity) and 3153 to 5594 (backscattering maps using 0.05% laser intensity). The Raman-
fluorescence maps were constructed using signal to axis intensity values from 1315 to 1345 cm
-1
. 
The intensity of the laser at 1058.22 nm was used for constructing the backscattering maps. 
Rainbow color scheme is chosen for representing the intensity in the maps, where violet 
represents the lowest intensity and red represents the highest intensity of the scattered light. 
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5.3.4 Imaging of NDs with Cells using Laser Scanning Confocal Microscopy 
To evaluate whether NDs can be detected in the cells based upon their intrinsic 
fluorescence, laser scanning confocal microscopy was performed. Hela cells seeded at the 
density of 40,000 cells per well were allowed to adhere to coverslip placed in 12-well plate, for 
24 hours. The media of cells were replaced with 1 mL of NDs dispersion prepared at a 
concentration of 50 µg/mL. After 6 hours, FBS was added to the media of the cells at the final 
concentration of 10%. The cells were incubated for a total of 24 hours and then washed three 
times with PBS (5 minutes each). Slides of the live cells were prepared and imaged with a Leica 
TCS SP5 laser scanning confocal microscope (Leica Microsystems Inc., Benshein, Germany; 
WCVM, University of Saskatchewan, Saskatoon, Canada) using 63X oil immersion objective. 
The sample excitation was carried out with 476 nm argon laser source and the emission was 
collected from 492 to 677 nm. A total of 44 z-sections of cells were imaged, each with the step 
size of 0.38 µm.  
5.3.5 MTT Assay  
The cytotoxicity of pNDs and fNDs in serum and serum free medium was evaluated in 
Hela cells by MTT assay. The stock dispersions of pNDs and fNDs at a concentration of 250 
µg/mL were prepared in serum and serum-free EMEM. A two-fold serial dilution from the stock 
preparation of NDs was carried out to reach a concentration of 4 µg/mL. The cells were plated in 
96-well cell culture plates at the density of 5,000 cells per well (100 µL volume) and allowed to 
adhere for 24 hours. The media of the cells were replaced with 100 µl volume of each dilution of 
NDs (with serum and without serum). After 24 hours, the treatments were removed from the 
cells followed by PBS washing. The cells were incubated for another 48 hours to perform MTT 
assay. 10 µl of sterile MTT stock solution (5 mg/mL of MTT in PBS) diluted in 90 µl of 
supplemented EMEM was added to each well, and the plates were incubated at 5% CO2/37ºC for 
45 minutes. Thereafter, the supernatant containing excess MTT solution was removed and the 
plates were dried gently. The formazan crystals resulting from the reduction of MTT were 
extracted in DMSO by shaking the plates for 10 minutes on a plate shaker. The plates were 
incubated at 37ºC for 10 minutes to remove any air bubbles formed during shaking. To prevent 
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any interference in reading absorbance that may occur due the ND particles, the plates were 
centrifuged at 160 g for 10 minutes. The supernatant from the each well was transferred to the 
new 96-well plates and the absorbance was read at 550 nm using microplate reader (BioTek
®
 
Microplate Synergy HT, VT, U.S.A.). The cells grown under the same conditions without ND 
treatment were used as controls. The mean absorbance of the control cells was set to 100% and 
consequently, the cellular viability was calculated as percent viability based on the formula: 
                   
                 
                 
                                    
5.3.6 Fluorescence Activated Cell Sorting (FACS) 
FACS was used to evaluate the transfection ability of fNDs-siRNA complex. Hela/GFP 
cells were seeded in a 6-well plate at the density of 1×10
5
 cells per well and allowed to adhere 
for 24 hours. The fNDs-siRNA complex was prepared at the weight ratio of 35:1 fNDs:siRNA as 
described in Chapter 4, section 4.2.10. Lipofectamine was used as a positive control for 
delivering the siRNA to the cells and cells with no siRNA treatment were used as a control. The 
cells were treated with fNDs-siRNA, Lipofectamine-siRNA and naked siRNA at a final siRNA 
concentration of 60 nM. After 7 hours, the Lipofectamine-siRNA treatment was removed (due to 
high toxicity of Lipofectamine) and fresh supplemented media was added to the wells. On the 
remaining wells, after 7 hours of treatment, the media was supplemented with FBS to the final 
concentration of 10%. After 24 hours of treatment, the media from all the wells were aspirated 
and replaced with the fresh supplemented media, and the plates were incubated for another 48 
hours. 
Thereafter, the cells were washed three times with PBS (5 minutes each), harvested using 
trypsin (0.25%)-EDTA, and resuspended in supplemented EMEM media (10% FBS). The cell 
suspension was transferred into a 5-mL flow cytometry tube and GFP knockdown was measured 
by BD FACSCalibur
TM
 (BD Biosciences, CA, USA) flow cytometer using a 488-nm excitation 
laser. A total of 10,000 events were recorded per sample. The GFP fluorescence was measured 
using 585/42 nm (FL2) band pass filters with the detector voltage set to 392 V. The signals were 
amplified using logarithmic mode with the amplification gain of 1. The forward scatter (volatge-
E1, mode-linear, amplitude gain-3.35) and side scatter (voltage-334, mode-linear, amplitude 
  
 
   117 
  
 
gain-1.00) excluded the cell debris. Data were analyzed using BD CellQuest
TM
 Pro software 
(version 6.0). To quantify the GFP knockdown, the histogram (GFP intensity versus number of 
events) was divided into four equal quadrants, and assigned low, mild, moderate and high GFP 
fluorescence intensity regions. The relative percentage GFP intensity shown by the treatment 
groups was determined by combining the populations of moderate and high GFP intensity 
quadrants, and then comparing those with the untreated cells. 
5.3.7 Statistical Analyses 
MTT results are expressed as the mean of n=3 ± S.E.M, where each n is derived from the 
average of 3 individual measurements. Scheffé post-hoc multiple comparison tests was used for 
statistical analyses when the sample variance was homogenous. In case of non-homogenous 
variance, Dunnett’s T3 post-hoc multiple comparison test was used. The significant differences 
were considered at p<0.05 level. SPSS program version 19.0 was used. 
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 Results and Discussion 5.4
5.4.1 Interaction of NDs with Human Cells  
The cellular interaction of NDs was examined using the techniques of Raman-
fluorescence and backscattering mode microspectroscopic mapping. 
5.4.1.1 Raman-Fluorescence Microspectroscopic Mapping  
Raman microspectroscopy has the potential to detect the NDs by identifying the unique 
diamond signal at 1332 cm
-1 
[8] with an advantage of lateral spatial resolution of 1-2 µm, greater 
than infrared (5 µm) [11]. The high fluorescence of NDs observed during their Raman spectral 
acquisition (Chapter 4, section 4.3.2, Figure 4.2) led to the hypothesis that the Raman spectrum 
obtained from the regions of the cells with NDs would show higher signal intensity with respect 
to the axis (fluorescence) compared to the cellular regions devoid of NDs. Therefore, the Raman 
maps of the cells in this experiment were constructed using the signal to axis intensity from 1315 
to 1345 cm
-1
 wavenumbers. This could theoretically provide information about interaction of 
NDs with the cells.  
The Raman-fluorescence maps of pNDs (Figure 5.2B) and fNDs (Figure 5.3B) treated 
cells when compared with the control cells (Figure 5.1B), revealed very high signal to axis 
intensity (red region).  Green and blue colored areas near the membrane of the NDs treated cells 
can also be observed (Figure 5.2B and 5.3B), which might indicate the interaction of NDs with 
cell membranes. The green color was more prevalent in the fNDs-treated cells (Figure 5.3B) 
compared to the cells treated with the pNDs (Figure 5.2B) in the selected intensity range. This 
might to be attributed to the higher fluorescence or cellular interaction ability of fNDs compared 
to the pNDs. The cationic fNDs might have interacted with the negatively charged cellular 
membrane more favorably than the negatively charged pNDs, which could ultimately lead to 
cellular internalization of fNDs. The white light images of the control (Figure 5.1A), pNDs 
treated (Figure 5.2A) and fNDs treated (Figure 5.3A) cells are also shown.  
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Figure 5.1: Raman-fluorescence and backscattering mode maps of untreated cells.  
 
Untreated cells: (A) white light image; (B) Raman-fluorescence map constructed using the signal 
to axis intensity from 1315−1345 cm–1 region; (C) backscatter map constructed using the 
intensity of elastically scattered light at 1058.22 nm using 0.1% laser intensity source (D) 
backscatter map constructed using the intensity of elastically scattered light at 1058.22 nm using 
0.05% laser intensity source. No Raman and backscattering signals are observed in the intensity 
range of 3400 to 4000 and 3153 to 5594,
 
respectively. The colors range from violet (lowest 
intensity) to red (highest intensity). Each scale bar is 20 µm. 
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Figure 5.2: Raman-fluorescence and backscattering mode maps of pristine carboxylated 
nanodiamond treated cells. 
  
Pristine carboxylated nanodiamond treated cells: (A) white light image; (B) Raman-fluorescence 
map constructed using the signal to axis intensity from 1315−1345 cm–1 region; (C) backscatter 
map constructed using the intensity of elastically scattered light at 1058.22 nm using 0.1% laser 
intensity source. The colors range from violet (lowest intensity) to red (highest intensity). Each 
scale bar is 20 µm. 
                                                                                                                                                                                                                      
  
 
   121 
  
 
Figure 5.3: Raman-fluorescence and backscattering mode maps of lysine-functionalized 
nanodiamond treated cell. 
 
Lysine-functionalized nanodiamond treated cell: (A) white light image; (B) Raman-fluorescence 
map constructed using the signal to axis intensity using 1315−1345 cm–1 region; (C) backscatter 
map constructed from the intensity of elastically scattered light at 1058.22 nm using 0.05% laser 
intensity source. The colors range from violet (lowest intensity) to red (highest intensity). Each 
scale bar is 10 µm. Representative data. Other analyzed cell also showed cellular interaction of 
lysine-functionalized nanodiamonds with a somewhat different pattern (red region located inside 
rather than near the cellular membrane). 
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However, the Raman maps of pNDs and fNDs treated cells were equivocal with regards 
to the cellular association of NDs for two reasons. Firstly, the detection of the diamond Raman 
signal of NDs with cells was challenging due to the intrinsic fluorescence exhibited by the cells 
and NDs, as shown in the Raman-fluorescence spectra obtained from one of the highest intensity 
region of cells treated with pNDs (Figure S 5.1) and fNDs (Figure S 5.2). Moreover, the Raman 
intensity of diamond signal became weak with the decrease in the size of diamond [12], 
contributing to the challenges of identifying the diamond peak embedded in the fluorescence 
with a single spectral acquisition. Secondly, the Raman-fluorescence maps did not reveal the 
existence of the individual ND particles or aggregates of NDs in the cells, rather, the entire cell 
showed high signal to axis intensity, bringing ambiguity to the results. It is important to mention 
here that the fNDs used in this study emitted fluorescence upon excitation with blue, green and 
red light sources as detected with conventional fluorescence microscope. 
Therefore, it became important to apply another technique, which in corroboration with 
the Raman maps can provide a better insight on the cellular interaction ability of the NDs.  
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5.4.1.2 Backscattering mode Mapping 
Considering the high refractive index of diamonds (2.4), it could be possible to identify 
these particles in the cells by measuring the intensity of elastically scattered light. NDs scatter 
the light elastically with a higher intensity than the same-sized cellular structures [13] since the 
refractive indices of cellular materials is almost half (~1.35 to ~1.7) of the diamond [14]. 
Synthetic diamond nanocrystals (55 nm) have been identified in the cells using differential 
interference contrast microscopy and have shown potential to act as scattering label [15].  
 Hence with an aim of identifying the cellular association of detonation NDs, the same 
area of the gold substrate with cells that was scanned for Raman spectroscopic measurements, 
was scanned to measure elastically scattered light. The backscatter map of the pNDs treated cells 
showed high intensity red region (surrounded by the green region) only near one end of the cells 
(Figure 5.2C), when compared to the control cells (Figure 5.1C). No red color was observed in 
any other region of the cells. However a clearly distinct blue colored region accompanied by the 
indigo colored region can be observed near the inner cellular membrane, in contrast to the central 
region of cells that showed violet color (least intensity). The backscatter map of the fND-treated 
cells (Figure 5.3C) demonstrated clear distinct red regions near the cellular membrane and also 
towards the center of the cells, when compared with the controlled cells (Figure 5.1D). 
Hence, the backscattering mode mapping demonstrated the interaction of fNDs with the 
cells. It should be noted that no NDs were observed in the white light images of NDs treated 
cells, which could be attributed either due to the smaller size of NDs that is beyond the resolution 
power of Raman microspectroscopy or due to the cellular internalization of NDs themselves. 
Although the backscattering maps provided evidence of cellular interaction of fNDs with cells, 
however, it was not clear if the NDs were present inside the cells or on the surface of cells. 
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5.4.1.3 Laser Confocal Scanning Microscopy  
With an aim of examining the cellular internalization ability of fNDs, laser scanning 
confocal microscopy was carried out on Hela cells cultured in the media containing fNDs. As the 
NDs used in this study did not show bright fluorescence emission at a particular wavelength, 
therefore the images was collected over a wide emission range [16]. The brightfield (A), 
fluorescence (B) and overlay of brightfield and fluorescence (C) images of the top, middle and 
bottom z-positions of fND treated Hela cell are shown (Figure 5.4). The top, middle and bottom 
section corresponds to the 44
th
, 22
nd
 and 1
st
 section, respectively. An overlay of brightfield and 
fluorescence image of middle slice of fND treated live cell revealed internalization of few fND 
particles, as marked by the red circle (Figure 5.4C, middle). These particles appear to be 
localized near the nucleus of the cell. However the fluorescence of these particles in the middle 
z-section was not distinctly identified due to the interference originating from cellular 
autofluorescence. The overlay of fluorescence and brightfield image of four consecutive slices 
from the middle (21
st
 ) towards the bottom of the cell revealed more distinct fND fluorescence 
emission, since the autofluorescence from the cell was less dominating towards the bottom of the 
cell (Figure 5.5C).  
It was revealed that the NDs used in this study had their own fluorescence, but the 
emission was not bright enough to be detected distinctly by the confocal fluorescence 
microscopy. It should be noted that these detonation NDs were not irradiated and annealed, 
which might create the (N-V) color centers emitting bright fluorescence with high photostability 
[17,18]. Therefore, in the future studies it will be necessary to irradiate the NDs with high energy 
sources such as proton, electron or helium ions, followed by thermal annealing to create the 
bright color centers in the NDs, which could be detected by the confocal microscopy. However, 
from this preliminary study, it could be suggest that the fNDs are able to internalize into the 
cells, although not at a high rate. 
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Figure 5.4: Laser scanning confocal microscopic images of the live cell treated with lysine-
functionalized nanodiamonds. 
 
Laser scanning confocal microscopic of Hela cells incubated with lysine-functionalized 
nanodiamonds for 24 hours: From left to right- (A) fluorescence images, (B) bright field images 
and (C) overlay of fluorescence and bright field images. Excitation was performed using 476 nm 
laser and emission was collected from 492 to 677 nm. A total of 44 slices were images with 0.38 
µm intervals. 
 
A C B 
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Figure 5.5: Laser scanning confocal microscopic images of four consecutive sections from 
middle towards the bottom of the cell treated with lysine-functionalized nanodiamonds. 
 
Laser scanning confocal microscopic of four consecutive sections from the middle towards 
bottom of the Hela cells incubated with lysine-functionalized nanodiamonds for 24 hours. From 
left to right; (A) fluorescence images, (B) bright field images and (C) overlay of fluorescence 
and bright field images. From top to bottom; sections 21, 20, 19 and 18 (intervals of 0.38 µm). 
Excitation was performed using 476 nm laser and emission was collected from 492 to 677 nm.  
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5.4.2 Cytotoxicity Assay 
It is crucial to test the cytotoxicity of the delivery agent before proceeding to the 
optimization of its transfection efficacy. Using Hela cell line, cytotoxic effects of seven different 
concentrations of NDs, ranging from 4 to 250 µg/mL incubated with cells for 24 hours, in the 
presence and absence of serum, were studied.  In these experiments, none of the examined 
concentrations of pNDs showed statistically significant differences in cellular viabilities 
compared to control and 4 µg/mL pNDs treated cells (Scheffé post-hoc multiple comparison test, 
p<0.05), indicating biocompatibility of pNDs towards the Hela cells (Figure 5.6). In addition, the 
presence or absence of serum during the treatment did not contribute to any considerable changes 
in the cellular viabilities (Figure 5.6). The overall mean cellular viabilities after treatment with 
pNDs in the absence of serum ranged from 88.70 to 102.27%, while the cells incubated with 
pNDs in presence of serum showed a mean cellular viability from 100.79 to 108.87%. This 
indicates, that although not significant, the pNDs with serum have a proliferative effect on the 
cells since the observed mean cellular viability was greater than 100% with all the tested 
concentrations, in agreement with Schrand et al [10]. However, the cytotoxicity results are in 
disagreement with Li et al who demonstrated that NDs in the absence of serum in cell culturing 
media cause extreme toxicity to the cells [4].    
The fNDs also had negligible cytotoxic effects on Hela cells as none of the tested 
concentration showed significant differences in cell viabilities compared to control and 4 µg/mL 
fND treated cell population, both in presence and in absence of the serum in the cell culture 
medium (Figure 5.7, Dunnett’s T3 post-hoc multiple comparison test, p<0.05). The mean cellular 
viability ranged from 86.61 to 105.24% in fNDs treated cells with serum, which decreased 
slightly to 84.44 to 99.50% when the serum was excluded from the treatment medium. Overall, 
the percentage viability of the cells incubated with fNDs (Figure 5.7) was a little lower than that 
observed with pNDs (Figure 5.6). This can be attributed to the highly positive surface charge of 
the fNDs (+48.9 mV) [19].  
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Figure 5.6: MTT cytotoxicity assay of Hela cells treated with pristine carboxylated 
nanodiamonds with and without serum. 
 
Evaluation of Hela cell viability after incubation with 0-250 µg/mL of pristine carboxylated 
nanodiamonds in the cell culture medium with and without serum for 24 hours as determined by 
MTT assay. Cells cultured without nanodiamonds were used as controls. Cells treated with 
pristine carboxylated nanodiamonds did not elicit significant cytotoxic effects when compared to 
control cells (Scheffé's post-hoc multiple comparison test, p<0.05). Results are expressed as 
mean ± S.E.M., n=3. 
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Figure 5.7: MTT cytotoxicity assay of Hela cells treated with lysine-functionalized 
nanodiamonds with and without serum. 
 
Evaluation of Hela cell viability after incubation with 0-250 µg/mL of lysine-functionalized 
nanodiamonds in the cell culture medium with and without serum for 24 hours as determined by 
MTT assay. Cells cultured without nanodiamonds were used as control group. Cells treated with 
lysine-functionalized nanodiamonds did not elicit significant cytotoxic effects when compared to 
control cells (Dunnett’s T3 post-hoc multiple comparison test, p<0.05). Results are expressed as 
mean ± S.E.M., n=3. 
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This cytotoxicity assay demonstrated that the NDs do not possess inherent cellular 
toxicity as supported by other studies [2,3,9], when used in the concentration range from 4 to 250 
µg/mL. However, these results cannot be generalized as many other factors such as type of cell 
line, impurities, functionalization and size of nanoparticles can ultimately affect the behavior of 
NDs in biological systems [20]. However, the NDs used in this study exhibit high 
biocompatibility towards Hela cell line. 
5.4.3 fNDs as siRNA Delivery Agents 
The siRNA is a double stranded fragment of RNA possessing 21-23 nucleotides that has 
recently gained interest for silencing the specific gene expression [21]. After being internalized 
into the cells, one strand of siRNA assembles into RNA induced silencing complex (RISC) 
depending upon the structural features of siRNA [22]. Argonaute 2, a catalytic element of RNA 
induced silencing complex, activates the RISC complex by cleaving the sense strand of siRNA 
[23,24], which subsequently releases its antisense strand free to degrade the complementary 
mRNA released from the nucleus into the cytoplasm of the cell [25]. The activated RISC 
continues its silencing effect until it undergoes degradation or a significant dilution below the 
therapeutic level [26]. RNA-interference mediated silencing induced by siRNA has early found 
early applications in treating hepatitis B [27], cancer [28,29], ocular neovascularization [30] and 
acute liver failure [31]. Therefore the key of success for silencing gene expression is in 
delivering siRNA efficiently into the cytoplasm of the cell and making it available for cleaving 
the complementary post-transcriptional mRNA. As described in chapter-1 (section 1.2), the 
anionic nature of siRNA provide barrier for its effective internalization across the negatively 
charged cellular surface, bringing the need for a carrier that could effectively deliver siRNA into 
the cytoplasm of cells.  
The fNDs demonstrated potential to act a siRNA delivery agent (Chapter 4, section 
4.3.4), therefore its efficacy to deliver anti GFP-siRNA in Hela/GFP cells was evaluated by flow 
cytometry. The majority of the gated untreated Hela/GFP cells were found in the moderate 
(42%) followed by the high GFP (30%) intensity quadrants, while the mild and low GFP 
intensity regions consisted of only 17% and 11% of the gated events, respectively (Figure 5.8A). 
Lipofectamine, a commercially available transfecting agent, when used as a siRNA delivery 
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agent substantially shifted the Hela/GFP cell population towards the lower GFP intensity 
regions, with only 2% and 22% of the gated cells remaining in the high and moderate GFP 
intensity quadrants, respectively (Figure 5.8B). The fNDs:siRNA (35:1,w/w/) as a transfection 
complex also shifted the cell population towards the lower GFP intensity, with 15% and 39% 
cells appearing in low and mild GFP intensity quadrants, respectively (Figure 5.8C). But a 
similar shift was also observed in the naked siRNA treated Hela/GFP cells, which showed 30% 
and 31% of cell population in the low and mild GFP intensity regions, respectively (Figure 
5.8D). Overall, the Lipofectamine-siRNA (positive control) knocked the GFP intensity down by 
66% (Figure 5.9) relative to the untreated group. The fNDs-siRNA knocked down the GFP 
intensity by 36%, which was 9% less than that observed with naked siRNA treated cells (45%). 
 This indicates that fNDs might not be able to release the siRNA efficiently from the 
fNDs-siRNA complex into the cytoplasm, limiting the GFP knockdown efficiency of the siRNA. 
The higher number of cells in mild GFP and fewer in low GFP intensity quadrant in fND-siRNA 
treated cells (Figure 5.8C) compared to the naked siRNA treated cells (Figure 5.8D) also 
indicates the inability of fNDs to release siRNA efficiently from the fNDs-siRNA complex. This 
brings forward the need of grafting a moiety on NDs surface that can facilitate the cytoplasmic 
release of siRNA from the fNDs. In addition, another methodology such as real time polymerase 
chain reaction or western blotting could be explored to quantitate the mRNA level of the cells.  
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Figure 5.8: Flow cytometer histograms indicating the GFP fluorescence intensity trend in 
untreated and treated cell populations. 
 
Fluorescence activated cell sorting histograms of (A) control; (B) Lipofectamine:siRNA 
transfected; (C) fNDs:siRNA (35:1,w/w) transfected; (D) naked siRNA transfected Hela/GFP 
cells. 
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Figure 5.9: The effect of using lysine-functionalized nanodiamonds to deliver small 
interfering RNA.  
 
Percentage GFP intensity of control Hela/GFP cells, Lipofectamine:siRNA, fNDs:siRNA (35:1) 
and  naked siRNA transfected Hela/GFP cells. The fluorescence intensity of green fluorescent 
protein was measured by flow cytometer and is expressed as a percentage relative to the 
untreated Hela/GFP cells. The lower knockdown by lysine-functionalized nanodiamonds-siRNA 
complex indicates the inefficient intracellular release of siRNA from the complex.  
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 Conclusions 5.5
In this study, the high fluorescence of NDs and cells limited the use of Raman 
microspectroscopy in detecting the diamond signal of NDs interacting with the cells. However, 
the maps constructed by measuring the elastically scattered light have higher potential for 
identification of the NDs in the cells. The comparison of fluorescence and backscattering maps 
of fND-treated and untreated cells provided a clear evidence of interaction of fNDs with cells. 
Laser scanning confocal microscopic measurements suggested the internalization of few particles 
of fNDs. The pNDs and fNDs demonstrated high biocompatibility in Hela cells up to 250 µg/mL 
concentration, with no considerable alterations in cell viability by the presence or absence of 
serum in the treatment media. siRNA interference suggested that the binding of fNDs to the 
siRNA might be to too strong to release the nucleic acid efficiently in the cytoplasm of the cells, 
suggesting the need for optimization of the formulation.  
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 Supplemental Data 5.7
Figure S 5.1: The Raman spectra obtained from a high intensity region of pNDs treated 
cells. 
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Figure S 5.2: The Raman spectra obtained from a high intensity region of fNDs treated 
cells. 
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 CONCLUSIONS AND FUTURE DIRECTIONS Chapter 6
 Overall Conclusions  6.1
The present study has probed two main dimensions for developing nanodiamonds (NDs) 
as a vector for improving the cellular delivery of nucleic acids. The first phase consisted of 
functionalization, physiochemical characterization and evaluation of potential of NDs for 
delivering genetic materials into the cell. The second phase probed the interactions of this novel 
delivery agent with the human cellular systems. 
Phase I 
NDs have potential to act as a superior delivery agent over many currently available 
carriers but remained unnoticed for several years due to their strong aggregation tendency. 
Recently, the techniques using high energy such as bead-assisted probe sonication and milling 
have been put forth to achieve single-digit-sized nanoparticles; however contamination, re-
aggregation as well as structural alterations remain the issue. The mechanochemical 
disaggregation approach used in this study successfully generated highly stable lysine-
functionalized NDs (fNDs) with size less than 50 nm. Not only these nanoparticles showed high 
stability in the water, which is considered to be biologically most suitable formulation dispersal 
medium, but were also resistant to re-aggregation upon solvent removal.  
The suitability of fNDs generated in this study as nucleic acid delivery agent is reflected 
by their ability to bind plasmid DNA and small interfering RNA by forming complexes with a 
size and surface charge favorable for cellular internalization. In the drug delivery studies, 
generally, the efficacy shown by a carrier for one particular type of genetic material is applied 
for other nucleic acids as well. However, from this study, it can be clearly concluded that even 
though all the nucleic acids are negatively charged, their interactions with positively charged 
solid-core carriers are peculiar depending mainly upon dimensions of the nucleic acids. 
Phase II 
NDs, both carboxylated and lysine-modified, used in this study were non-cytotoxic 
towards mammalian cells, therefore potentially suitable for in vivo formulation development. 
Backscattering microscopic mapping revealed the successful interaction of this material either 
with the cellular surface or intracellular region, or both. The fluorescence emission from the 
fNDs was weak to be detected efficiently by confocal microscopy; however, the evidence of 
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internalization of few particles was present. High cellular interaction accompanied by the low 
cytotoxicity of fNDs supports the use of these nanoparticles as a delivery vehicle. However fND 
particles obtained in this study were not able to improve the delivery efficacy of small interfering 
RNA in human cervical cancer cells as studied by using fluorescence activated cell sorting. 
In conclusion, fND particles developed in this study have potential to emerge as a 
suitable candidate for delivering nucleic acids; however efficacy remains to be seen. 
 Future Directions 6.2
This study was the first attempt by our research group for developing amino acid-
functionalized NDs as potential gene delivery agent. The successful 
disaggregation/functionalization approach established by this study paved the way for future 
studies on this carbon material. Moreover, this study explored various techniques for in vitro 
detection of ND particles, from which the best techniques would be used directly for future 
studies.  
The future directions will focus on two major aspects of NDs as delivery agent: 
6.2.1 Cellular Uptake Studies on NDs 
The internalization of pristine carboxylated and fNDs will be tested in human cell line 
using laser scanning confocal microscopy. For future studies, the NDs will be irradiated with 
proton, electron or helium ion beam, and then annealed at 800℃, to create bright 
photoluminescent nitrogen vacancy color centers able to be detected effectively by confocal 
fluorescence microscopy. In addition, for more comprehensive cellular internalization 
investigations, synchrotron directed scanning transmission X-ray spectromicroscopy (STXM) 
will also be carried out based upon its feasibility to distinguish NDs from the cellular 
composition, as evidenced by a pilot study (Appendix B)  
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6.2.2 Quantification of mRNA Level in fNDs-Delivered siRNA 
Real-time polymerase chain reaction assay or western blotting will be carried out in 
future to quantitate the gene knockdown effect shown by fNDs-siRNA formulation. These 
techniques can measure the actual cellular GFP-mRNA level reduction; therefore will be more 
specific and selective than measuring the overall cellular fluorescence intensity. Based upon 
these results, the optimization of NDs formulation will be carried out, if required. Incorporation 
of the lipids such as 1,2-di-(9-octadecenoyl)-glycero-3-phosphoethanolamine (DOPE) and 1,2-
dioleoyl-3-trimethylammonium-propane (DOTAP) could be considered if fNDs will be 
confirmed to have too strong binding with siRNA. Addition of DOPE to the gemini surfactants, 
synthesized by our research group, has increased the transfection efficacy of plasmid DNA.   
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APPENDIX A                                                                                                    
PRELIMINARY ATTEMPTS TO ACHEIVE DISGGREGATION OF NDs 
Following is the summary of the attempts made to disaggregate pristine carboxylated 
NDs (pNDs), using bath sonication, probe sonication, grinding media and surfactants, before 
proceeding to the lysine functionalization. 
 The pNDs at the concentration of 2 mg/mL was dispersed in water and sonicated for 4 
hours in a bath sonicator. No decrease in the aggregate size of pNDs was observed (A.1). 
Dispersion of pNDs prepared in 0.5% aqueous solution of benzalkonium chloride, at a 
concentration of 2 mg/mL, with 4 hours of bath sonication experienced a decrease in aggregate 
size of pNDs showing a peak at 255 nm (A.2). However the size distribution was very broad 
ranging from 90 to 1000 nm (A.2). Keeping all the other parameters same, dispersion of pNDs 
was also prepared in 2% aqueous solution of Tween 80, but with no improvement in the particle 
size (A.3). The sonication of pNDs dispersed in water was carried out in presence of 0.05 mm 
YTZ
®
 grinding media, which also did not result any considerable disaggregation of pND 
aggregates (A.4). A summary of the Z-Average size, polydispersity index and zeta potential of 
all these attempts is provided in A.5.  
Further efforts were made to disaggregate pND aggregates using high power probe 
sonication. To observe, if there is any time dependent effect of sonication in achieving 
disaggregation of pNDs, probe sonication of aqueous dispersions of pNDs was carried out from 
5 to 45 minutes (A.6). A summary of Z-Average size, polydispersity index and zeta potential 
achieved through this technique is presented in A.7. Similarly, the probe sonication was also 
performed for pNDs dispersed in 1% Tween 80, in the presence of 0.05 mm YTZ
®
, at various 
time intervals (A.8). None of these attempts resulted in a considerable disaggregation of pNDs.  
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A.1: Size distribution graph of pristine carboxylated nanodiamonds dispersed in water (2 
mg/mL) with 4 hours of bath sonication. 
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A.2: Size distribution graph of pristine carboxylated nanodiamonds (2 mg/mL) dispersed 
in 0.5% aqueous solution of benzalkonium chloride with 4 hours of bath sonication. 
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A.3: Size distribution graph of pristine carboxylated nanodiamonds (2 mg/mL) dispersed 
in 2% aqueous solution of Tween 80 with 4 hours of bath sonication. 
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A.4: Size distribution graph of pristine carboxylated nanodiamonds (2 mg/mL) dispersed 
in water with 4 hours of bath sonication in presence of 0.05 mm YTZ
®
 grinding media. 
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A.5: Size, polydispersity index and zeta potential measurement of pristine carboxylated 
nanodiamond samples obtained after bath sonication 
 
 
  
Sample 
Z-Average size 
(nm) 
Polydispersity 
index 
Zeta Potential 
(mV) 
pNDs (2 mg/mL)  dispersed in water 
with 4 hours of sonication 
880.1 0.45 -18.7 
pNDs (2 mg/mL)  dispersed in 0.5 % 
aqueous solution of benzalkonium 
chloride with 4 hours of sonication 
241.9 0.18 46.3 
pNDs (2 mg/mL) dispersed in 2% 
aqueous solution of Tween 80 with 4 
hours of sonication 
 
716.8 
 
0.64 -12.7 
pNDs (2 mg/mL) dispersed in water 
with 4 hours of bath sonication in 
presence of 0.05 mm YTZ® grinding 
media 
1100 0.57 -20.2 
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A.6: Aqueous dispersions of pristine carboxylated nanodiamonds (2 mg/mL) obtained by 
probe sonication at various time intervals. 
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A.7: Size, polydispersity index and zeta potential measurement of aqueous dispersions of 
pristine carboxylated nanodiamonds (2 mg/mL) at various time intervals obtained by 
probe sonication in the presence of 0.05 mm YTZ
®
 grinding media 
 
 
 
  
Sonication time (minutes) 
Z-Average size 
(nm) 
Polydispersity index 
Average zeta 
potential (mV) 
5 957.5 0.71 -20.4 
10 1857 0.92 -16.4 
15 563.6 0.46 -21.8 
20 2028 0.87 -15.3 
25 5137 1.00 -8.24 
45 2071 1.00 -20.0 
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A.8: Pristine carboxylated nanodiamonds (2 mg/mL) dispersed in 1% Tween 80 at various 
time intervals using probe sonication in the presence of 0.05 mm YTZ
®
. 
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APPENDIX B 
A PILOT STUDY TO EVALUATE THE FEASIBILITY OF SCANNING TRANSMISSION X-
RAY SPECTROMICROSCOPY TO IDENTIFY NANODIAMONDS IN THE 
MAMMALIAN CELLS 
Soft X-ray spectromicroscopy of the cells incubated with fNDs was carried out using 
scanning transmission X-ray spectromicroscope (STXM) at the beamline 10ID-1 of the Canadian 
Light Source (University of Saskatchewan, Saskatoon, SK, Canada).  The advantages associated 
with STXM include high spatial resolution (less than 50 nm) [1,2], non-interference from the 
fluorescence of cells or NDs, and no need of staining the cellular structures. A375 cells were 
plated on silicon nitride windows, placed in a 24-well cell culture plate, at the density of 10,000 
cells per well, and allowed to adhere for 24 hours. After treating with NDs for 2 hours, the 
samples were sent to CLS for the soft X-Ray microscopic measurements.  
To fulfill the requirements for the identification inside the cells, the NDs should possess a 
unique identifiable STXM spectrum. Spectra from the four different regions of NDs (B.1A) at 
the C 1s edge were recorded to examine the possibility of identifying these nanoparticles in the 
cells in the future studies. All the spectra were same with same absorption peaks at C 1s edge 
(B.1B), supporting the potential of STXM in detecting NDs in the cells. Measurements at the C 
1s edge from six different regions of a single cell treated with NDs (B.2A) revealed three 
different spectral patterns (B.2B and C). In stack 1 (B.2B), the green and blue colored spectra 
were identical; while pink spectra showed absorption peaks at somewhat different energy range. 
The blue and green colored spectral pattern were assigned to proteins, while the pink colored 
pattern arose due to the lipids present in the cells, as discussed in other studies [1,3,4]. The 
spectra shown in stack 2 (B.2C) were identical to the spectra obtained from NDs alone (B.1B). 
Therefore, these spectra indeed can be assigned to the NDs. Subsequently by fitting these 
spectra, the presence of NDs (B.3A), lipids (B.3B) and proteins (B.3C) was revealed, indicated 
by the brighter regions in the respective figures. The constructed color image of the scanned 
cellular region clearly revealed the cellular composition and association of NDs (B.4); where 
blue colored region corresponds to the lipids of the cell, green indicates the cellular proteins and 
red demonstrates NDs. The magenta color observed in the cells is due to the overlap of the red 
and blue colors, indicating the association of lipids with NDs.  
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B.1: X-ray absorption C 1s-edge spectra of nanodiamonds.  
 
(A) Scanning transmission X-Ray microscopic image of nanodiamonds; (B) X-ray C 1s-edge 
spectra of the marked areas recorded by scanning transmission X-Ray microscope. The spectra 
obtained from four different regions of nanodiamonds showed same spectral pattern. 
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B.1: X-ray absorption C 1s-edge spectra of nanodiamond treated cell. 
 
(A) Scanning transmission X-Ray microscopic image of a single A375 cell incubated with 
nanodiamonds; (B) and (C) C 1s-edge spectra of the marked areas recorded by scanning 
transmission X-ray microscope revealing association of nanodiamonds with cell. 
  
Stack 1 Stack 2  
A 
B C 
  
155 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.2: Grey scale scanning transmission X-Ray microscopic map of a single A375 cell treated 
with nanodiamonds. 
 
The brighter region indicates the distribution of (A) nanodiamonds; (B) proteins; (C) lipids.   
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Proteins          
    Lipids     
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C 
1 μm 
1 μm 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.3: Color coded scanning transmission X-ray microscopic composite map of a single A375 
cell treated with nanodiamonds. 
   
(Upper) Color coded scanning transmission X-Ray microscopic composite map of nanodiamond 
treated A375 cell revealing lysine-functionalized nanodiamonds, proteins and lipids; (Bottom) C 
1s-edge X-ray absorption spectra as recorded by scanning transmission X-ray microscope. Red, 
nanodiamonds; green, protein; blue, lipids; magenta, nanodiamonds associated with lipids. 
  
                 NDs                                              Lipids                                            Proteins          
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Therefore, STXM has the potential to identify the NDs and will be used in future studies to 
reveal the origin of ND signals, after optimization of the sample preparation. 
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APPENDIX C                                                                                                             
PERMISSION LETTERS FOR REPRODUCING FIGURES 
C.1: Permission to reproduce Figure 2.2A  
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